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Abstract
men who have unprotected receptive anal intercourse 
with men, whether the source partner is known to be 
HIV positive or not; heterosexuals after unprotected 
receptive anal intercourse; and intravenous drug users 
sharing needles with a known HIV-positive person. PEP 
following non-occupational exposure to HIV was cost-
effective for all male–male intercourse (unprotected 
receptive and insertive anal intercourse, unprotected 
receptive oral sex, and ‘other’) and was possibly cost-
effective for intravenous drug users and high-risk 
women. Four additional studies were identified giving 
further information about adverse events associated 
with PEP after non-occupational exposure to HIV. The 
majority of participants experienced adverse events with 
the most common being nausea and fatigue. Rates were 
generally higher in participants receiving triple therapy 
than in participants receiving dual therapy. Completion 
of PEP therapy was variable, ranging from 24% to 78% 
of participants depending on type of therapy. Toxicity 
was the main reason for discontinuation of treatment.
Conclusions: It is not possible to draw conclusions 
on the clinical effectiveness of non-occupational PEP 
for HIV because of the limited evidence available. 
The review of cost-effectiveness suggests that non-
occupational PEP may be cost-effective, especially in 
certain population subgroups; however, the assumptions 
made and data sources used in the cost-effectiveness 
studies mean that their results should be used with 
caution.
Non-occupational postexposure prophylaxis for HIV:  
a systematic review
J Bryant,* L Baxter and S Hird
Southampton Health Technology Assessments Centre (SHTAC), Wessex Institute for Health Research 
and Development, University of Southampton, Southampton, UK
*Corresponding author
Objective: To review the evidence on the clinical 
effectiveness and cost-effectiveness of non-occupational 
postexposure prophylaxis (PEP) for HIV.
Data sources: Eleven electronic databases were 
searched from inception to December 2007.
Review methods: Selected studies were assessed, 
subjected to data extraction using a standard template 
and quality assessment using published criteria. Studies 
were synthesised using a narrative approach with full 
tabulation of results from all included studies.
Results: One clinical effectiveness study meeting the 
inclusion criteria was identified, a cohort study of PEP 
in a high-risk HIV-negative homosexual male cohort 
in Brazil. The quality of the study was generally weak. 
Seroincidence in the cohort as a whole (2.9 per 100 
person-years) was very similar to that expected in 
this population (3.1 per 100 person-years, p > 0.97), 
despite the seroconversion to HIV being 1/68 in the 
PEP group and 10/132 in the group not receiving 
PEP . High-risk sexual activities declined over time 
for both PEP and non-PEP users. Four economic 
evaluations met the inclusion criteria of the review. The 
methodological quality of the studies was mixed. The 
studies are constrained by a lack of published data on 
the clinical effectiveness of PEP after non-occupational 
exposure, with effectiveness data derived from one 
study of occupational PEP . Their generalisability to 
the UK is not clear. Results suggest that PEP following 
non-occupational exposure to HIV was cost saving for © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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ART antiretroviral therapy
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HIV human immunodeficiency virus
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MSM men who have sex with men
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PEP postexposure prophylaxis
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ZDV zidovudine
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Background
Human immunodeficiency virus (HIV) is a sexually 
transmitted and bloodborne virus found primarily 
in the blood, semen or vaginal fluid of an infected 
person. It is transmitted in two main ways: by 
having unprotected sex (anal, vaginal or oral) 
with someone infected with HIV or by sharing 
needles and syringes with someone infected with 
HIV. Postexposure prophylaxis (PEP) for HIV 
is the prompt administration of antiretroviral 
therapy following known or potential exposure 
to HIV infection in an attempt to prevent the 
establishment of infection. The effectiveness of PEP 
in preventing seroconversion (i.e. converting from 
HIV negative to HIV positive, with the detection 
in the blood of antibodies to HIV) after non-
occupational exposure to HIV is unclear.
Objectives
The main aim of this study was to review the 
evidence on the clinical effectiveness and cost-
effectiveness of non-occupational PEP for HIV.
Methods
A systematic review of the evidence was undertaken 
using a priori methods.
Data sources
Eleven electronic databases were searched from 
inception to December 2007. Bibliographies of 
related papers were assessed for relevant studies 
and experts contacted to identify additional 
published references.
Study selection
Studies were included if they fulfilled the following 
criteria:
Intervention: any antiretroviral drug regimen  •	
administered as non-occupational PEP for 
a short period (28 days) to HIV-negative 
people potentially exposed to HIV through 
unprotected sexual contact or use of a 
potentially contaminated needle or potentially 
contaminated biological fluid.
Participants: humans with non-occupational  •	
exposure to HIV through unprotected sexual 
exposure (oral, vaginal, anal), either voluntary 
or rape, with an HIV-infected partner or 
partner of unknown HIV status; humans with 
exposure to a needle contaminated by a known 
or potentially infected substance in a non-
occupational setting.
Comparator: no intervention; group not  •	
receiving PEP; a different PEP regimen.
Outcomes: HIV seroconversion frequency;  •	
adverse effects and complications of PEP; 
adherence to PEP; health-related quality of life; 
costs or some measure of cost-effectiveness.
Design: randomised controlled trial,  •	
controlled clinical trial, cohort study or 
case–control study; cost-effectiveness/utility 
studies; economic evaluations; prospective 
observational studies for adverse events.
Studies identified were assessed for inclusion in 
two stages with titles and abstracts and full papers 
of retrieved studies assessed independently by two 
reviewers, with differences in decisions resolved 
through discussion or through recourse to a third 
independent reviewer.
Data extraction and 
quality assessment
Data were extracted by two reviewers using a 
data extraction form developed a priori. Any 
disagreements were resolved through discussion 
or through recourse to independent assessment 
by a third reviewer. The methodological quality 
of the studies included in the systematic review 
was assessed by means of modified quality 
assessment tools using individual components 
of methodological quality rather than relying on 
summary scores. The quality criteria were applied 
by two reviewers, with any disagreements resolved 
through discussion or through recourse to a third 
independent reviewer.
Executive summaryExecutive summary
x
Data synthesis
Studies were synthesised using a narrative 
approach with full tabulation of results from all 
included studies.
Results
Number and quality of studies
One clinical effectiveness study meeting the 
inclusion criteria for the review was identified. 
This was a cohort study of PEP in a high-risk HIV-
negative homosexual male cohort in Brazil. The 
methodological quality and the quality of reporting 
of the study were generally weak.
Four economic evaluations met the inclusion 
criteria of the review (three conducted in the US 
and one in France). The methodological quality 
of the studies is mixed. Each of the studies is 
constrained by a lack of published data on the 
clinical effectiveness of PEP after non-occupational 
exposure, with effectiveness data derived from one 
study of occupational PEP. Their generalisability to 
the UK is not clear.
Summary of clinical effectiveness
Seroincidence in the cohort as a whole (2.9 per 100 
person-years) was very similar to that expected by 
the study authors in this population (3.1 per 100 
person-years, p > 0.97), despite the seroconversion 
to HIV being 1/68 in the PEP group and 10/132 in 
the group not receiving PEP. The study reported 
that, on average, high-risk sexual activities declined 
over time for both PEP and non-PEP users. The 
study authors concluded that a public health PEP 
programme would not have a major impact on HIV 
transmission in the study population.
Summary of cost-effectiveness
Results from the included economic studies suggest 
that PEP following non-occupational exposure to 
HIV is cost saving for men who have unprotected 
receptive anal intercourse with men, whether the 
source partner is known to be HIV positive or not; 
heterosexuals after unprotected receptive anal 
intercourse; and intravenous drug users sharing 
needles with a known HIV-positive person.
PEP following non-occupational exposure to HIV 
was cost-effective for all male–male intercourse 
(unprotected receptive and insertive anal 
intercourse, unprotected receptive oral sex, and 
‘other’). PEP following non-occupational exposure 
to HIV was possibly cost-effective for intravenous 
drug users and high-risk women.
Adverse events
Four additional studies (two comparative studies 
and two observational studies) were identified 
that supplied further information about adverse 
events associated with PEP after non-occupational 
exposure to HIV. The majority of participants 
experienced adverse events with the most common 
being nausea and fatigue. Rates were generally 
higher in participants receiving triple therapy than 
in participants receiving dual therapy. Completion 
of PEP therapy was variable, ranging from 24% to 
78% of participants depending on type of therapy. 
Toxicity was the main reason for discontinuation of 
treatment.
Conclusions
It is not possible to draw conclusions on the 
clinical effectiveness of non-occupational PEP for 
HIV because of the limited evidence in terms of 
quantity and quality of studies. Only one cohort 
study was identified that met the inclusion criteria 
for the systematic review. Cost-effectiveness has 
been assessed in four economic evaluations using 
evidence on effectiveness taken from the use of PEP 
in the occupational setting. Results are consistent 
across studies and suggest that non-occupational 
PEP may be cost-effective, especially in certain 
population subgroups. Although the studies have 
been conducted in an appropriate way and may 
have internal validity in terms of the structure of 
the model and plausible results, the assumptions 
and data sources mean that results should be used 
with caution. The generalisibility to the UK of 
studies conducted in the US is not clear as sexual 
behaviour and HIV incidence may not be similar.
Suggested research priorities
The most important research need is to establish 
the clinical effectiveness of non-occupational PEP 
within the UK. Ongoing research in the form of the 
NONOPEP project, an MRC-funded surveillance 
programme of PEP for non-occupational exposure 
to HIV, will address aspects of clinical effectiveness 
in terms of seroconversion rates in people who take 
PEP compared with those who do not and evaluate 
problems associated with taking antiretroviral 
medications. This project is due for submission 
shortly. Data generated from this study can then 
be assessed and used to inform future economic 
modelling of the cost-effectiveness of non-
occupational PEP in the UK.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 1  
Aim of the review
to review the evidence on the costs and cost- •	
effectiveness of non-occupational PEP for HIV
to make recommendations for future research. •	
If appropriate, and if sufficient time and resources 
allow, an additional aim will be to develop an 
economic evaluation or adapt an existing one to 
model costs and cost-effectiveness in preventing 
seroconversion after non-occupational PEP for 
HIV.
T
he aim of this project is to evaluate the effects 
of non-occupational postexposure prophylaxis 
(PEP) for human immunodeficiency virus (HIV) 
with a course of antiretroviral therapy.
The main objectives are as follows:
to review the evidence on the clinical  •	
effectiveness of non-occupational PEP for HIV
to summarise the best relevant evidence on the  •	
harms of non-occupational PEP for HIV© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Description of underlying 
health problem
Human immunodeficiency virus is a sexually 
transmitted and bloodborne virus found primarily 
in the blood, semen or vaginal fluid of an infected 
person. HIV is transmitted in two main ways:
by having unprotected sex (anal, vaginal or  •	
oral) with someone infected with HIV
by sharing needles and syringes with someone  •	
infected with HIV.
Human immunodeficiency virus can also be 
transmitted through blood infected with HIV 
and being exposed as a fetus or infant to HIV 
before/during birth or through breastfeeding. 
Any person is at risk of infection with the virus if 
he or she is exposed to HIV through unprotected 
sex, contaminated blood products or HIV-infected 
bodily fluids.1
Seroconversion (converting from HIV negative to 
HIV positive) occurs when antibodies to HIV can be 
detected in the blood after infection with the virus. 
In individuals who become infected with HIV after 
exposure to the virus, about 30–70% experience 
an acute seroconversion illness, typically between 
2 and 6 weeks after exposure to the virus. The 
onset is acute and the illness lasts for 1–2 weeks. 
Its severity varies from a mild glandular fever-like 
illness with fever, sore throat, lymphadenopathy 
and a non-itchy maculopapular rash to a severe 
illness associated with mucocutaneous ulceration 
and neurological manifestations that requires 
treatment in hospital.2
Human immunodeficiency virus has a prolonged 
‘silent’ period during which it often remains 
undiagnosed, particularly as the seroconversion 
illness (if present) may have been very mild. More 
persistent or severe symptoms may not appear for 
10 years or more after HIV first enters the body in 
adults, or within 2 years in children born with HIV 
infection. This period of asymptomatic infection 
varies greatly in each person. Some people may 
begin to have symptoms within a few months 
whereas others may be symptom-free for more than 
10 years.3
Human immunodeficiency virus acts by attacking 
and destroying CD4 (cluster of differentiation) 
cells. These cells are a type of white blood cell 
called T lymphocytes (or helper/inducer cells), 
which are important in the body’s immune system. 
Their depletion during HIV infection results 
in susceptibility to infection from opportunistic 
diseases such as tuberculosis, pneumonia and 
some cancers.4 A CD4 cell count (a measure of 
the number of CD4 cells in a specified volume of 
blood) gives a measure of the degree to which an 
individual’s immune system is ‘compromised’. It 
helps to identify periods in which an individual 
is more vulnerable to opportunistic infections, 
consequently helping inform decisions to initiate 
antiretroviral treatment and therapies to prevent 
these infections.4 Acquired immunodeficiency 
syndrome (AIDS) is diagnosed in the UK when 
an HIV-infected individual presents with an 
AIDS-defining illness, such as Pneumocystis 
carinii pneumonia, pulmonary tuberculosis or 
extrapulmonary tuberculosis.5
The seroprevalence of HIV is the number of 
cases of HIV present in a specific population 
at a designated time, where a case is defined as 
someone who has HIV antibodies in their serum.6 
Information on the seroprevalence of HIV in 
the UK relies on case and test result reporting. 
However, this can only give information on 
diagnosed infections. It is therefore supplemented 
by a programme of unlinked anonymous surveys 
(using the residue of specimens collected for 
routine testing for other purposes), which provide 
information about the total seroprevalence, 
including both diagnosed and undiagnosed 
infections, in population subgroups.6
The most effective methods for preventing HIV 
infection are preventive behaviours including 
sexual abstinence, having sexual relations only 
with a non-infected partner, correct condom use, 
abstinence from drug-injection use and consistent 
use of sterile equipment when using injection 
drugs. However, secondary prevention measures 
such as prophylactic antiretroviral drugs have 
been used to reduce the risk of HIV infection after 
occupational or non-occupational exposure.7
Chapter 2  
BackgroundBackground
4
Epidemiology
Globally there are an estimated 39.5 million 
people living with HIV. There were 4.3 million new 
infections in 2006, with 2.8 million (65%) of these 
occurring in sub-Saharan Africa and important 
increases in Eastern Europe and Central Asia, 
where there are some indications that infection 
rates have risen by more than 50% since 2004. 
In 2006, 2.9 million people died of AIDS-related 
illnesses.8
The most recent figures for the UK estimate that 
in 2006 there were 73,000 people living with HIV 
in the UK, around one-third of whom had not yet 
been diagnosed. There were an estimated 7800 
reports of new diagnoses of HIV infection in 2006. 
A total of 59% of these were among heterosexuals, 
36% in men who have sex with men (MSM) and 
2.5% in intravenous drug users. In terms of ethnic 
group, 46% of persons newly diagnosed were black 
African and 42% were white.9
There are certain groups in the UK who are at 
higher risk of infection than others:
homosexual men (MSM) •	
injecting drug users (IDUs) •	
men and women who have lived as adults in  •	
countries where heterosexual transmission 
of HIV is common (notably South, East and 
Central Africa)
children, from their infected mothers during  •	
pregnancy and birth.1
Table 1 shows the prevalence of HIV infection in 
different population subgroups in the UK.10
Description of the 
intervention
Postexposure prophylaxis for HIV is the prompt 
administration of antiretroviral therapy following 
known or potential exposure to HIV infection in an 
attempt to prevent the establishment of infection.11 
TABLE 1  HIV seroprevalence in different population subgroups in the UK
Community group HIV seroprevalence (%)
Homosexual men 
London 20.3
Scotland 3.2
Elsewhere 3.6
Heterosexuals (region of birth) Male Female
UK 0.5 0.2
Rest of Europe 2.0 0.2
North America 2.9 0.1
Central and South America 2.4 0.9
Caribbean 1.2 1.0
North Africa and Middle East 0.5 0.4
Sub-Saharan Africa 6.9 11.3
South Asia 0.5 0.6
East and South-East Asia 0.5 0.7
Australasia 0.8 0.1
Injecting drug users
London 2.9
Elsewhere in the UK 0.5© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Animal models show that, after initial exposure, 
HIV replicates within dendritic cells of the skin 
and mucosa before spreading through lymphatic 
vessels and developing into a systemic infection. 
This delay in systemic spread leaves a ‘window of 
opportunity’ for PEP using antiretroviral drugs 
designed to block replication of HIV.12 However, 
the evidence for the effectiveness of PEP in 
preventing seroconversion after non-occupational 
exposure to HIV is unclear.
Current UK guidance on PEP for non-occupational 
potential or actual exposure to HIV, based on the 
limited evidence available on the effectiveness of 
PEP after occupational exposure,10,12,13 recommends 
combination therapies. Although there is no direct 
evidence that they are more effective in preventing 
HIV post exposure than monotherapies, 
combination therapies are more efficacious in 
treating HIV-infected patients and in preventing 
perinatal transmission than monotherapies and 
so it is theorised that a combination of drugs 
would enhance the effectiveness of PEP.12 As yet, 
no antiretroviral drug has been licensed for use 
after non-occupational exposure to HIV in the 
UK.13 The current drug regimen recommended 
for HIV PEP starter packs after non-occupational 
exposure14 is:
one Combivir •	  (GlaxoSmithKline) tablet 
(300 mg zidovudine + 150 mg lamivudine) twice 
daily, plus
two Kaletra •	  (Abbott)  film-coated tablets 
(200 mg lopinavir + 50 mg ritonavir) twice daily.
Current UK guidance suggests that other drug 
combinations could be used when the physician 
considers them more appropriate for individual 
patients, such as including in the regimen 
ritonavir-boosted lopinavir, saquinavir or 
amprenavir.13 However, the current evidence on 
which drug regimen to use, the effectiveness of that 
regimen in preventing seroconversion following 
non-occupational exposure to HIV and adherence 
rates to different regimens is unclear. The guidance 
is based upon effectiveness of antiretroviral therapy 
in individuals chronically infected with HIV and on 
limited data of toxicity in PEP.
There are potential risks associated with PEP 
following non-occupational exposure or potential 
exposure to HIV. The drugs used have side 
effects such as gastrointestinal upset (nausea and 
diarrhoea), diabetic exacerbation, dangerous 
interactions with other drugs and nephrolithiasis.12 
These side effects can increase non-adherence, 
which in turn can lead to seroconversion of the 
patient and the development of drug-resistant 
strains.12 There is also the potential for an increase 
in risk behaviours if PEP is perceived as preventing 
HIV infection.7
Current UK practice
Current UK practice for prescribing PEP after 
non-occupational exposure to HIV is based on 
guidance issued by the Department of Health13 and 
guidelines from the British Association for Sexual 
Health and HIV (BASHH).10
The Department of Health guidance (2004) 
states that the lack of evidence of effectiveness 
of PEP following non-occupational exposure 
to HIV prevents a recommendation either in 
favour of or against its use.13 It suggests that 
expert advice should be sought urgently from a 
physician experienced in the treatment of HIV 
(or a paediatrician in the case of a child) in the 
event of any non-occupational exposure to HIV 
that is considered to carry a high risk of HIV 
infection.13 For optimal efficacy PEP should 
ideally be started within an hour of exposure, but 
as this time frame is unlikely to be met in non-
occupational exposures to HIV the risk of PEP 
failure is increased. However, longer periods from 
exposure should not be considered an absolute 
contraindication to PEP.13 A risk assessment of the 
circumstances surrounding the exposure should 
be made by the physician considering prescribing 
PEP, to determine the risk of infection.13 The 
guidance states that all of the considerations that 
apply to the prescription of PEP after occupational 
exposure apply equally to non-occupational PEP 
from the point of a decision being reached that 
it is appropriate to prescribe it.13 The current 
recommended drug regimen has been outlined in 
the previous section.
The BASHH guidelines make recommendations 
for the use of PEP following potential sexual 
exposure to HIV (PEPSE).10 The recommendation 
is that PEPSE is given within 72 hours following 
unprotected vaginal or anal intercourse with an 
HIV-positive source or receptive anal intercourse 
with a source of unknown HIV status but from a 
group of > 10% HIV prevalence. It is suggested 
that patients complete 4 weeks of antiretroviral 
therapy and reattend for HIV testing at 3 months 
and 6 months post exposure.10 The recommended 
drug regimen has been outlined in the previous 
section.Background
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A recent audit of practice against these guidelines 
suggests that PEPSE is being prescribed and 
dispensed as the BASHH guidelines recommend, 
but that completion rates for the full course of 
medication [53%, 95% confidence interval (CI) 
40.84–64.21] and attendance for 3 and 6 months 
postexposure HIV testing (12%, 95% CI 5.56–
21.29) are low.15
A survey of UK genitourinary medicine clinics 
in 1999 found that there were 242 requests for 
prophylactic antiretroviral drugs made at 56 clinics 
following a potential non-occupational exposure 
to HIV.11 In total, 60% of these requests were made 
to nine clinics, six of which were located in the 
London area. The survey also found that there 
had been a fourfold increase in the number of 
requests for prophylactic antiretroviral drugs and a 
sevenfold increase in the number of prescriptions 
between 1997 and 1999.11 Most of the requests had 
come from HIV-serodiscordant couples who had 
either had unprotected sex (13 cases, 29%) or had 
condom breakage during sex (10 cases, 22%).
Costs
One cost estimate suggests that the drug cost of a 
full 28-day course of PEP is approximately £600 
(not including staff time,) whereas the lifetime costs 
of treatment for an HIV-positive individual are 
estimated to be between £135,000 and £181,000.10
Issues specific to non-
occupational HIV exposure
There are a number of factors specific to non-
occupational HIV exposure that impact on 
establishing the effectiveness of PEP in this 
situation or that have particular implications 
which are different from those in occupational 
exposures.16
Ethical issues
The study types available to investigate the efficacy 
of PEP for non-occupational exposures are limited 
as it is not deemed ethical to randomly allocate 
subjects to an intervention or a control group after 
such an exposure. No controlled trials are likely to 
take place for this reason.7
Time from exposure 
to PEP initiation
As mentioned in the section on current UK 
practice, current UK guidance on the use of PEP 
for non-occupational exposure to HIV recommends 
that PEP should be considered when individuals 
present within 72 hours of exposure.10 This 
contrasts with guidance for initiation of treatment 
within 1 hour of occupational exposure.13 The 
average length of time between non-occupational 
exposure and presentation at health services is 
unknown. One study of requests for PEP from UK 
genitourinary medicine clinics found that the time 
interval between exposure and request was known 
for 141 out of 242 requests for PEP.11 Out of these 
141 requests, 116 (82%) were made within 48 
hours.
Potential multiple exposures to 
HIV pre- and post-PEP initiation
Unlike occupational exposure to HIV in which 
the exposure incident will usually be a single 
exposure, non-occupational exposures to HIV can 
be multiple.16
There is a possibility that HIV infection could take 
place as a result of another exposure immediately 
before the exposure that led to PEP being 
sought.16 Individuals presenting for PEP after 
non-occupational exposure who subsequently 
seroconvert have reported additional potential 
exposures (with partners known to be HIV 
positive or with unknown HIV status) between 
initiating the PEP regimen and their subsequent 
seroconversion.16 This, combined with potential 
multiple exposures before PEP, makes it difficult to 
determine whether seroconversion resulted from 
failure of PEP or from other exposures.16
Virus concentration
A high plasma viral load in the source may 
increase the risk of transmission.10 Although low or 
undetectable plasma viral loads probably reduce 
the risk, transmission may still be possible.10 
Although viral loads in the genital tract normally 
correlate with plasma viral loads, it is possible 
to have a detectable genital viral load with an 
undetectable plasma viral load.10 This may be 
important in non-occupational exposures, where 
the exposures may be repeated.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Knowledge of HIV 
status of source
In many circumstances the estimated risk of 
HIV transmission following non-occupational 
exposure is greater than that following 
occupational exposure in which PEP is routinely 
considered (Table 2).10 Homosexual men having 
unprotected receptive anal intercourse with a 
known HIV-positive source have an estimated 
risk of transmission of 3% (or a 1 in 33 chance 
of infection).10 This compares with an estimated 
risk of transmission of 0.3% (1 in 333 chance of 
infection) following a needlestick injury when the 
source is HIV positive.10
In occupational exposure the HIV status of the 
source may already be known or there may be 
an opportunity to establish the HIV status of 
the source. In non-occupational exposure the 
HIV status of the source may also be known, 
for example in known HIV-discordant partners. 
However, the HIV status of the source may not be 
known and it may be very difficult or impossible to 
find out. This could make calculating the estimated 
risk of transmission after non-occupational 
exposures less accurate. The proportion of requests 
for PEP after non-occupational exposure for which 
the HIV status of the source is unknown is not 
currently established.
Furthermore, knowledge of the HIV status of the 
source is important because it may lead to better 
prescribing of antiretrovirals, for example in cases 
in which the source is known to have a drug-
resistant strain of HIV. This can lead to higher 
adherence to medication and potentially greater 
effectiveness in preventing seroconversion.
Concomitant exposures 
to other pathogens
Risky sexual behaviour places individuals at 
risk of sexually transmitted infections other 
than HIV, such as gonorrhoea and syphilis.13 
Exposure through sharing drug-injecting 
equipment can expose a person to the risk of other 
bloodborne infections such as hepatitis B and 
C.13 Epidemiological studies have shown that the 
presence of other sexually transmitted infections 
enhances HIV transmission.10
The impact of local trauma 
on the risk of transmission
Breaches in the mucosal barrier as a result of 
trauma (e.g. following sexual assault or first 
intercourse) may increase the risk of HIV 
acquisition.10 Menstruation or other bleeding may 
also facilitate transmission.10
Non-compliance with therapy 
and follow-up testing
As mentioned previously in the section on 
description of the intervention, the drugs used to 
prevent HIV seroconversion have side effects such 
as gastrointestinal upset (nausea and diarrhoea), 
diabetic exacerbation, dangerous interactions with 
other drugs and nephrolithiasis.12 Because of this 
the BASHH guidelines state that these potential 
side effects need to be considered in situations in 
which the presenting patient is in a state of acute 
anxiety but the assessment of risk of transmission 
is low.10
TABLE 2  Risk of HIV transmission following an exposure from a known HIV-positive individual10
Type of exposure Estimated risk of HIV transmission per exposure (%)
Blood transfusion (one unit) 90–100
Receptive anal intercourse 0.1–3.0
Receptive vaginal intercourse 0.1–0.2
Insertive vaginal intercourse 0.03–0.09
Insertive anal intercourse 0.06
Receptive oral sex (fellatio) 0–0.04
Needlestick injury 0.3 (95% CI 0.2–0.5)
Sharing injecting equipment 0.67
Mucous membrane exposure 0.09 (95% CI 0.006–0.5)
CI, confidence interval.Background
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Patients have cited side effects as a reason for 
discontinuing PEP after sexual exposure.15 The 
BASHH guidelines recommend that at least 75% 
of people receiving PEP following sexual exposure 
to HIV should complete the 4-week course of HIV 
therapy, and at least 75% should attend for a 3- 
and 6-month follow-up HIV test.10 However, one 
study15 found that only 53% (95% CI 40.84–64.21) 
of patients completed therapy and only 12% 
(95% CI 5.56–21.29) attended for both a 3- and 
6-month follow-up HIV test. They speculate that 
this low completion rate may reflect recipients 
independently clarifying their source’s HIV status, 
poor documentation of adherence and/or a high 
default rate from follow-up, with patient-perceived 
low risk, inadequate recall of non-attendees and a 
mobile population also contributing.15
Poor adherence to PEP regimens is important as it 
may theoretically result in the acquisition of a drug-
resistant virus should the individual become HIV 
infected.10
Behavioural impact of PEP 
availability and programmes
There are concerns that the availability of PEP 
for non-occupational exposure to HIV will reduce 
commitment to primary prevention strategies such 
as using a condom during sex or avoiding needle 
sharing when injecting drugs. This could lead to 
a rise in the frequency of high-risk behaviours, 
thereby adding to, rather than lessening, HIV 
transmission.10,17 The most desirable outcome is 
that promoting PEP will cut rates of HIV infection 
in exposed individuals and reinforce safer sexual 
behaviour.17
A number of possible scenarios have been 
envisaged including:
no impact of availability of PEP on behaviour •	
negative impact: availability of PEP results in  •	
an increase in risky behaviours
positive impact: the ‘close call’ may act  •	
to motivate and sustain risk reduction 
in individuals who have engaged in risk 
behaviour.10
Currently there is conflicting evidence with 
different studies providing evidence for each of the 
three scenarios.10 At the moment there are no data 
suggesting that a significant number of individuals 
will repeatedly present for PEP following non-
occupational exposure.10
Another possible outcome of PEP for non-
occupational exposures is that the overall number 
of HIV infections remains unchanged because the 
numbers protected by PEP are counterbalanced 
by additional infections in individuals whose risk 
behaviour is increased by awareness of PEP but 
who then fail to use it.17 There is the potential for 
PEP to cause net harm by protecting only a few 
individuals at the expense of adverse effects on 
behaviour and increased HIV transmission in the 
wider community.17 There are also implications for 
the cost and cost-effectiveness of non-occupational 
PEP, particularly if the awareness of availability 
of PEP for non-occupational exposures leads 
to increased demand from those with a low-risk 
exposure.17 Although these are important concerns 
there does not appear to be much evidence to 
support or refute them.
Rationale for the study
There is growing clinical and patient enthusiasm 
for the use of non-occupational PEP to prevent 
HIV infection, although the reduction in the 
risk of seroconversion may be small, therapy can 
have unpleasant side effects and other issues 
as described may impact on effectiveness. No 
systematic review of the existing literature has 
been identified. Research is therefore needed 
to synthesise the available evidence on the 
effectiveness, harms and cost-effectiveness of non-
occupational PEP for HIV.
From the perspective of the patient the pressing 
clinical issue is to prevent HIV infection. The wider 
NHS perspective is the most appropriate and cost-
effective use of expensive antiretroviral drugs.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
he a priori methods used for the review 
are outlined in the research protocol (see 
Appendix 1). This was sent to members of the 
advisory group for the review for expert comments 
(see Acknowledgements). Helpful comments were 
received relating to the general content of the 
research protocol; no specific problems with the 
proposed methods of the review were identified.
Some changes, additions or points of clarification 
were made to the methods discussed in the original 
protocol.
It was felt important that a comparator group  •	
of some sort was included in any study that was 
considered for inclusion as evidence of clinical 
effectiveness. This could be either a group not 
receiving PEP, either through study design or 
by individual choice not to receive medication, 
or a group receiving an alternative drug 
regimen. As such, several studies that initially 
appeared to meet the inclusion criteria were 
excluded on the basis of not reporting relevant 
outcomes for comparator groups.
The main outcome of interest to assess the  •	
clinical effectiveness of non-occupational PEP 
for HIV was the HIV seroconversion rate. 
However, adverse events are also an important 
outcome measure and to supplement the 
limited adverse event data from the clinical 
effectiveness section of the report additional 
studies were sought. Studies that did not report 
the main outcome of interest (seroconversion 
rates) but which did present adverse event 
data for both an intervention group and a 
comparator group were included for adverse 
events, as were prospective observational 
studies that met the inclusion criteria in terms 
of population and intervention.
The research methods used for the systematic 
reviews are summarised below.
Search strategy
The following databases were searched for 
published studies and ongoing research, from 
inception to December 2007: the Cochrane 
Library (Database of Systematic Reviews and the 
Cochrane Central Register of Controlled Trials), 
MEDLINE (Ovid), EMBASE (Ovid), PubMed, 
NHS Economic Evaluations Database (NHS EED), 
NHS Health Technology Assessment database 
(NHS HTA), Database of Abstracts of Reviews of 
Effectiveness (DARE), EconLit, National Research 
Register (NRR), Current Controlled Trials and 
ClinicalTrials.gov. Grey literature and conference 
proceedings were also searched. Searches were 
restricted to the English language and to human 
studies. Bibliographies of identified papers were 
assessed for other relevant studies. Investigators 
of studies were not contacted because of time 
constraints. Further details, including key search 
terms, can be found in Appendix 2.
Inclusion and data 
extraction process
Titles and abstracts of studies identified by the 
search strategy were screened independently 
for inclusion by two reviewers. The full text of 
potentially eligible studies was obtained and 
examined independently for inclusion by two 
reviewers. Data from each of the included studies 
were extracted by two reviewers on standard data 
extraction forms. Any disagreements were resolved 
by consensus or arbitration by a third reviewer if 
necessary.
The process for identifying and including studies 
is illustrated in Appendix 2, Figure 1. The primary 
reason for excluding studies was that they did 
not meet the inclusion criteria; for example they 
did not have a comparator group or results were 
not presented separately for the intervention and 
comparator groups. A list of studies excluded 
at various stages of the process can be found in 
Appendix 3.
Quality assessment
The methodological quality of included studies 
was assessed using modified formal tools specific 
to the design of the study and focusing on possible 
sources of bias. The clinical effectiveness study 
Chapter 3  
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was assessed for quality using criteria developed 
by Spitzer et al.18 Quality assessment of economic 
evaluations was conducted using a checklist 
adapted from those developed by Drummond and 
Jefferson19 and Philips and colleagues.20
Quality criteria were applied to each included study 
independently by two reviewers. At each stage 
any differences in opinion were resolved through 
discussion or if necessary by arbitration by a third 
reviewer.
Inclusion criteria
The inclusion criteria used for studies of the 
clinical and cost-effectiveness of non-occupational 
PEP for HIV are shown below.
Intervention
Any antiretroviral drug regimen administered  •	
as non-occupational PEP for a short period 
(28 days) to HIV-negative people potentially 
exposed to HIV through unprotected sexual 
contact or use of a potentially contaminated 
needle or potentially contaminated biological 
fluid.
Population
Humans with non-occupational exposure to  •	
HIV. This may be by:
unprotected sexual exposure (oral, vaginal,    –
anal), either voluntary or rape, with an HIV-
infected  partner  or  partner  of  unknown 
HIV status
exposure  to  a  needle  contaminated  by  a    –
known or potentially infected substance in 
a non-occupational setting.
Comparator
No intervention. •	
Group not receiving PEP. •	
A different PEP regimen. •	
Outcomes
HIV seroconversion frequency. •	
Adverse effects and complications of PEP. •	
Adherence to PEP. •	
Health-related quality of life. •	
Costs or some measure of cost-effectiveness. •	
Study type
Randomised controlled trial (RCT), controlled  •	
clinical trial (CCT), cohort study or case–
control study.
Cost-effectiveness/utility studies. •	
Economic evaluations. •	
Prospective observational studies for adverse  •	
events.
Data synthesis
Synthesis of data was through narrative review with 
full tabulation of results of all included studies. Full 
data extraction forms are shown in Appendices 4 
and 5. Meta-analysis was not possible because of 
the limited data found.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Chapter 4  
Clinical effectiveness
Significant selection bias may have occurred 
during the recruitment of study participants. 
Participants were recruited from an unreported 
number of eligible participants of a previous HIV 
seroincidence study of MSM. A total of 250 of 
those deemed eligible were contacted by telephone 
and the first 200 to agree to participate were 
included in this study. The authors do not report 
the total number of eligible participants in the 
previous study or how the 250 eligible participants 
that were telephoned were selected, nor do they 
Quantity and quality of 
research available
One published study met the inclusion criteria for 
the review, which was a cohort study conducted by 
Schechter and colleagues21 in Brazil (Table 3, Figure 
1 in Appendix 2 and Appendix 4).
The methodological quality and the quality of 
reporting of the included study were generally 
weak (Table 4).
TABLE 3  Details of included study
Study  Population Intervention Comparison Outcome measures
Schechter et 
al. 200421
Brazilian cohort of 200 
high-risk men who 
have sex with men 
(MSM)
28-day course of PEP after potential high-
risk exposure to HIV (zidovudine 300 mg 
and lamivudine 150 mg orally, fixed-dose 
combination tablet twice daily)
Non-PEP 
users
Reported behaviour, 
PEP utilisation, adverse 
events, incident HIV 
infection
TABLE 4  Quality assessment of included study 
Yes U/I/Sa No DK/NRb N/A Comments
Proper random 
assignment
No
Proper sampling U 250 potential participants invited to participate by telephone; 
first eligible 200 who agreed were enrolled. Participants were 
given PEP to begin after an eligible exposure
Adequate sample 
size
U Authors comment that the 109 exposures for which PEP 
was taken represent a small proportion of the total eligible 
exposures that occurred during the study
Objective 
outcomes
I Self-reported high-risk sexual activity
Blind assessment No
Objective eligibility 
criteria
Yes
Reported attrition Yes
Comparability of 
groups
Yes
Generalisability U Limited to men who have sex with men from a previously 
known high-risk cohort, aged 18–35 years
a  U/I/S, uncertain/incomplete/substandard.
b  DK/NR, don’t know/not reported.Clinical effectiveness
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report any attempt to minimise volunteer bias. No 
power calculation is provided to justify why 200 
participants were needed.
Participants allocated themselves to the 
intervention or the control group depending on 
whether or not they initiated chemoprophylaxis 
after an eligible exposure by taking the 4-day 
supply of PEP that they had been given. If PEP 
was initiated, after 4 days the participant was 
assessed by study personnel to establish whether 
the exposure was considered a high enough risk 
to warrant a further 24 days of PEP. Further 
selection bias may have occurred at this point as 
the authors do not report what was considered to 
be a high-risk exposure or the procedure by which 
study personnel made such decisions. However, 
the authors do report the demographic and 
behavioural characteristics of all study participants, 
which suggests that there were no significant 
differences between those who did and those who 
did not use PEP over the course of the study.
The authors do not report blinding of study 
participants or personnel. Although it would not 
have been possible to have fully blinded both 
study personnel and participants, it may have been 
possible at the routine follow-up appointments to 
have blinded personnel to PEP use by participants. 
This could have reduced potential detection bias.
In the analysis the authors report that two 
participants had no follow-up data and were 
therefore excluded from analysis, meaning that an 
intention to treat analysis was not conducted. The 
authors report the seroincidence rate (incidence 
of seroconversions per 100 person-years) for all 
of the study participants together, compared with 
the expected number of incident HIV cases in 
the absence of PEP (modelled from the previous 
HIV incidence study). The authors state that 
they did this because of a lack of a control group 
(participants not taking PEP). However, the 
reported results seem to suggest that there is a 
control group with follow-up data (participants who 
did not initiate PEP after an eligible exposure). 
It is therefore not clear why the authors did not 
calculate the incidence of seroconversion for those 
who took PEP and for those who did not take PEP, 
to give an estimate of the effectiveness of PEP in 
preventing seroconversion for non-occupational 
exposures.
This study reports the use of PEP amongst a well-
established cohort of high-risk sexually active 
MSM, aged 18–35 years, in Rio de Janeiro, Brazil. 
The study cohort may have some similarities 
with populations of MSM living in other big 
cities, although the limited age range of study 
participants prevents generalisation to populations 
of MSM as a whole. It is also not possible to 
generalise the findings of this study to the 
population as a whole, in which potential exposure 
to HIV may also occur through heterosexual sex or 
non-occupational needlestick injuries.
Assessment of effectiveness
Tables 5–9 present the results of the included cohort 
study21 in terms of seroincidence of HIV within the 
cohort, PEP use, non-completion of PEP, adverse 
events and reports of risky behaviours.
Seroconversion to HIV
The HIV seroincidence is presented in Table 5. 
One incidence of seroconversion to HIV was 
reported in the group of participants that took 
PEP, compared with 10 from the ‘no PEP’ group. 
No p-value was reported. Over the course of the 
study the overall incidence of HIV was 2.9 per 
100 person-years (95% CI 1.4–5.1). The authors 
report that, based on the risk profile of the 
participants and experience from a previous study, 
the expected number of new HIV infections overall 
was 11.8 (p > 0.97 compared with the observed 11 
infections) and the expected seroincidence was 3.1 
per 100 person-years (p > 0.97 compared with the 
seroincidence of 2.9 found in this study).
TABLE 5  HIV seroincidence
PEP (n = 68) No PEP (n = 132) p-value
Seroconversion to HIV 1 10 Not reported© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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PEP use
The PEP use in the cohort is presented in Table 
6. In the majority of cases the full 28-day course 
was prescribed once per participant (72.1%). In 
total, 100 out of 109 exposures for which PEP was 
initiated by participants were considered eligible 
and received the 4-week course. The authors report 
that the most common reasons for not initiating 
PEP (≥ one possible response per participant) were 
sex with a steady partner (n = 150), the participant 
did not consider the exposure to be of sufficiently 
high risk to warrant PEP (n = 94) and concerns 
about side effects (n = 23).
Adverse events and adherence
The number of non-completed PEP courses is 
shown in Table 7. The authors report that the 
full 28-day regimen of PEP was completed for 
89 (89%) of the eligible exposures, including the 
participant who seroconverted, and that the 11 
discontinuations correspond to nine participants.
Two of the participants did not come back to the 
study site to complete their visits at 28 days.
There were seven discontinuations of PEP because 
of adverse events. At least one side effect was 
reported in 82% of episodes of PEP use. Nausea 
was the most commonly reported side effect: six of 
the discontinuations for adverse events were due 
to this. Apart from one patient with a history of 
pancreatitis who had to stop taking PEP because of 
an asymptomatic increase in pancreatic enzymes, it 
is reported that there were no clinically significant 
laboratory abnormalities among those receiving 
PEP.
Risk behaviours and PEP use
The median numbers of male partners reported 
by participants are presented in Table 8. These 
remained the same from the baseline visit to the 
last visit at 24 months for both groups, although 
the range was increased in both groups at the last 
visit.
Table 9 shows the types of risk behaviours that 
participants were asked to report and the changes 
from the 6 months previous to the baseline visit 
to the 6 months previous to the last follow-up 
visit at 24 months. Reported unprotected anal 
intercourse decreased in both groups; in the no 
PEP group this decrease was statistically significant. 
Reported unprotected oral intercourse decreased 
significantly in both the PEP and the no PEP 
groups. Unprotected vaginal intercourse increased; 
this was not statistically significant.
Self-reported results should be viewed with some 
caution where there is the possibility that high-
risk behaviour has been under-reported or where 
reports may be inconsistent.
TABLE 6  PEP use (28-day course)
PEP (n = 68) No PEP (n = 132)
Prescribed once, n (%) 49 (72.1) –
Prescribed twice, n (%) 14 (20.6) –
Prescribed three times, n (%) 2 (2.9) –
Prescribed four times, n (%) 2 (2.9) –
Prescribed nine times, n (%) 1 (1.5) –
TABLE 7  Non-completed PEP courses 
PEP (n = 68) No PEP (n = 132)
Did not return to complete course 2 –
Discontinued because of adverse events 7 –Clinical effectiveness
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TABLE 8  Numbers of male partners and PEP use
PEP (n = 68) No PEP (n = 132)
Median number of male partners 6 months 
before baseline (range)
4 (0–50)a 2 (0–40)b
Median number of male partners 6 months 
before last visit (range)
4 (0–180)a 2 (0–100)b
a  p = 0.43.
b  p = 0.46.
TABLE 9  Risk behaviours and PEP use 
PEP (n = 68) No PEP (n = 132)
6 months 
before 
baseline
6 months 
before last 
visit p-value
6 months 
before 
baseline
6 months 
before last 
visit p-value
Unprotected anal 
intercourse, n (%)
32 (47.1) 27 (39.7) p = 0.35 48 (36.4) 32 (24.2) p = 0.008
Unprotected oral 
intercourse, n (%)
16 (23.5) 8 (11.8) p = 0.06 32 (24.4) 16 (12.2) p = 0.002
Unprotected vaginal 
intercourse
1.6% 4.7% p = 0.16 6.1% 8.3% p = 0.26
Summary of clinical 
effectiveness of PEP 
for non-occupational 
exposure to HIV
One cohort study of PEP in a high-risk HIV- •	
negative homosexual male cohort in Brazil 
met the inclusion criteria of the review. The 
methodological quality and the quality of the 
reporting of the study were generally weak.
The seroconversion to HIV rate in this study  •	
was one in the PEP group and 10 in the non-
PEP group.
The results suggest that PEP made no  •	
difference to the expected seroconversion to 
HIV for this cohort.
Over the course of the study the overall  •	
seroincidence (combining the PEP and non-
PEP groups) was 2.9 per 100 person-years 
(95% CI 1.4–5.1). This was compared with 
the authors expected seroincidence of 3.1 per 
100 person-years (p > 0.97 compared with the 
observed seroincidence of 2.9).
PEP was rarely prescribed on more than two  •	
occasions per participant, with the majority 
(72.1%) receiving just one course.
The number of non-completed courses appears  •	
to be low, with only 2 out of 68 not returning 
to complete the course and 7 out of 68 
discontinuing because of adverse events.
The authors report that, on average, high- •	
risk sexual activities declined over time for 
both PEP and non-PEP users. This does not 
appear to be related to the decision to initiate 
PEP; both groups had access to interventions 
designed to prevent/reduce risk behaviour, 
including at each visit pre- and post-test 
counselling, provision of condoms and safer 
sex workshops.
The authors conclude that the results from  •	
their study ‘argue against establishing a public 
health PEP programme in our population 
with the aim of having a major impact on HIV 
transmission’ because of the observed overall 
seroincidence of 2.9% being so similar to that 
expected for this population.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
he aim of this chapter is to evaluate the cost-
effectiveness of non-occupational PEP for HIV. 
A systematic review of the literature was conducted 
to identify economic evaluations of the use of PEP 
in people with non-occupational exposure to HIV. 
The feasibility of developing an economic model 
was also considered.
The methods used for the systematic review are 
described in Chapter 3. The details of the inclusion 
and exclusion criteria are shown in Appendix 1 and 
the search strategies are shown in Appendix 2.
Titles and abstracts of studies identified by 
the search strategy were assessed for potential 
eligibility by two reviewers. The full text of relevant 
papers was obtained and inclusion criteria were 
applied to each study independently by two 
reviewers. Differences in opinion were resolved 
through discussion or by arbitration by a third 
reviewer if necessary.
Economic evaluations were eligible for inclusion 
if they reported on the cost or cost-effectiveness 
of any antiviral drug regimen administered as 
PEP in people with non-occupational exposure 
to HIV (unprotected sexual exposure or needle 
contamination) compared with another PEP 
regimen or a group of people not receiving PEP 
(Appendix 1).
Quantity and quality of 
research available
Four economic evaluations22–25 met the inclusion 
criteria for the review and are shown in Table 10 
(details in Figure 2 in Appendix 2 and Appendix 5).
A summary of the methodological quality of 
reporting in the four included studies is shown 
in Table 11. Each of the cost-effectiveness studies 
outlined a well-defined question: to assess the 
cost-effectiveness of PEP for HIV following a non-
occupational exposure.22–25 The patient group was 
clearly stated in three of the four studies.23–25 In 
the study by Pinkerton and colleagues22 the patient 
group is less clear as the authors have referred to 
a hypothetical cohort of 10,000 ‘patients’ (a cohort 
that includes women) but have used this term 
interchangeably with 10,000 ‘men who have sex 
with men’.
All of the studies clearly stated that their 
perspective was societal, with the analysis including 
all identifiable costs, regardless of who bore them. 
However, Pinkerton and colleagues22 stated only 
the monetary costs of PEP drugs and of treating a 
patient with HIV/AIDS. Herida and colleagues25 
referred only to health sector costs in their study, 
despite employing a societal perspective.
Two of the studies23,25 gave a clear description of 
the interventions considered. One study24 does 
not describe the PEP programme employed, 
whereas in the other22 the intervention applied to a 
hypothetical cohort was assumed to be zidovudine, 
lamivudine and indivadir, or zidovudine and 
lamivudine only, but no further details are given. 
Three of the four studies22,24,25 employed the 
comparator of ‘no PEP’ whereas in the fourth 
study23 the comparator used is unclear.
The study types used were appropriate for 
economic analysis in each case; three of the four 
studies included both cost-effectiveness and 
cost–utility analyses22,23,25 and one employed a cost–
utility analysis alone.24
Each of the four studies is limited as the 
effectiveness of the intervention, PEP in non-
occupational exposure to HIV, has not been 
established. The effectiveness parameter in each of 
the papers is based on the results of a case–control 
study undertaken in health-care workers who were 
prescribed zidovudine monotherapy. The dual 
or triple drug regimens considered in these cost-
effectiveness studies are assumed to be as effective 
as zidovudine alone in this study of occupational 
exposure. Pinkerton and colleagues22 have taken 
their effectiveness parameter, the probability that 
PEP is effective, from the original study,26 set at 
79%. The remaining three studies23–25 have taken 
their effectiveness parameter from the update of 
that study,27 in which effectiveness is set at 81%, 
although one of these studies25 reports that an 
effectiveness of 80% is used.
Chapter 5  
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TABLE 10  Study characteristics of economic evaluations
Pinkerton et al. 
199822 
Pinkerton et al. 
200423 
Pinkerton et al. 
200424  Herida et al. 200625 
Country of origin US US US France
Base year prices 1996 US$ 2000 US$ 2000 US$ 2002 Euros
Intervention PEP following potential 
HIV exposure through 
sexual contact with a 
partner who may or 
may not be infected vs a 
‘no programme option’. 
PEP was assumed to 
consist of a 4-week 
regimen of triple 
combination therapy 
with ZDV, 3TC and 
the protease inhibitor 
indivadir
Initial 7-day PEP with 
additional 21 days 
supplied at follow-up 
visit. Also medical 
evaluation, HIV risk 
assessment, risk-
reduction counselling. 
Response to medication 
of HIV-infected sources 
was obtained if possible 
to tailor PEP to that 
most appropriate 
Hypothetical PEP 
programme in 96 US 
metropolitan statistical 
areas (MSA), based 
on San Francisco PEP 
programme 
PEP programme vs 
‘no PEP’ alternative. 
Clinicians prescribe 
drugs of their choice 
(usually tri-therapy 
containing protease 
inhibitor). Antiretroviral 
drugs and counselling 
provided at each visit 
Study type Cost–utility analysis; 
decision-analytical 
model to evaluate cost-
effectiveness
Cost-effectiveness and 
cost–utility study
Cost–utility analysis Cost-effectiveness 
analysis based on 
decision trees and 
cost–utility study
Study group A hypothetical cohort 
of 10,000 patients 
who reported sexual 
intercourse with a 
partner of unknown 
HIV status
401 participants 
with possible non-
occupational exposure 
to HIV (sexual, 
needle sharing, 
non-occupational 
needlestick injury, other 
(bite or assault)
Information on PEP 
clients taken from the 
San Francisco PEP 
programme, which was 
used to estimate the 
number of potential 
PEP clients in each 
group in each MSA
12,551 individuals 
who sought PEP 
between July 1999 and 
December 2003; 8958 
(71%) were prescribed 
PEP and included in a 
national hospital-based 
voluntary surveillance 
of PEP programme 
for both occupational 
and non-occupational 
exposure
Perspective Societal  Societal  Societal Societal
Industry role None stated None stated (one 
of the authors has 
received honorariums 
from GlaxoSmithKline, 
Bristol-Myers 
Squibb and Agouron 
Pharmaceuticals)
Not stated Not stated
3TC, lamivudine; ZDV, zidovudine.
The effectiveness of PEP and its effects on the cost–
utility ratios presented in the studies, along with 
other parameters, are clearly explored in sensitivity 
analyses in each of the studies.22–25 Authors of two 
of the studies reported multivariate and threshold 
analyses in addition to the univariate sensitivity 
analysis.22,23
Costs and consequences were judged to have 
been valued credibly in three of the four included 
studies.22,23,25 Pinkerton and colleagues24 have 
calculated the costs of providing PEP from a 
previously published cost analysis.
Three of the four studies have used a lifetime 
horizon for analysis.22,24,25 A shorter time horizon 
of 10 years has been employed for estimating 
long-term infection, but no justification has been 
given.23 Discount rates are clearly reported in 
three studies. In two studies23,25 an annual rate of 
3% was used to discount both costs and benefits, 
such as future savings in averted HIV-related © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 11  Summary of the methodological quality of reporting of the cost-effectiveness studies
Quality criteria
Pinkerton et al. 
199822
Pinkerton et al. 
200423
Pinkerton et al. 
200424
Herida et al. 
200625
Is there a well-defined question? Yes Yes Yes Yes
Is there a clear description of 
alternatives (i.e. who did what to 
whom, where and how often)?
Unclear Yes No Yes
Has the correct patient group/
population of interest been clearly 
stated?
No Yes Yes Yes
Is the correct comparator used? Yes Unclear Yes Yes
Is the study type reasonable? Yes Yes Yes Yes
Is the perspective of the analysis clearly 
stated?
Yes Yes Yes Yes
Is the perspective employed 
appropriate?
Unclear Yes Yes Unclear
Is the effectiveness of the intervention 
established?
No No No No
Has a lifetime horizon been used for 
analysis? If not, has a shorter time 
horizon been justified?
Yes No Yes Yes
Are the costs and consequences valued 
credibly? 
Yes Yes Unclear Yes
Is differential timing considered? Yes Yes Unclear Yes
Is incremental analysis performed? Yes No No No
Is sensitivity analysis undertaken and 
presented clearly? 
Yes Yes Yes Yes
medical costs. Pinkerton and colleagues22 used a 
3% annual rate (applied to both costs and benefits) 
and altered this to 0% (undiscounted) and 5% in 
the sensitivity analysis. It is unclear if discounting 
has been applied in one of the 2004 Pinkerton and 
colleagues studies.24
Incremental analysis was reported by only one of 
the studies.22 The remaining three papers report 
cost–utility ratios but no incremental ratios. 
Pinkerton and colleagues23 compare their results 
with previously published papers.
Table 12 presents a summary of the external validity 
of the included cost-effectiveness studies. Three 
of the four studies are set in the US22–24 and the 
fourth in France,25 where the institutional health-
care arrangements and resource costs, and access to 
them, are not comparable to those in England and 
Wales. It is unclear whether the patient groups are 
similar to those of interest in England and Wales as 
these studies are set in differing health-care systems 
but are conducted among the relevant population: 
those taking PEP after a non-occupational 
exposure.
Either the intervention in each of the four studies 
was not sufficiently clear for a judgement to be 
made of treatment comparability24,25 or the research 
protocol included such elements as counselling and 
adherence counselling that may not be a feature of 
clinical management.23 Pinkerton and colleagues22 
have assumed that the PEP in their study consists 
of triple combination therapy, which is comparable 
to that recommended in the UK, but no further 
details are given.
Assessment of cost-
effectiveness
Summaries of the results of the four published 
economic evaluations in terms of cost–utility ratios 
for different population subgroups are shown in 
Tables 13–15.
Herida and colleagues25 found that the French 
PEP programme did not appear to be cost-
effective overall, with a cost-effectiveness ratio 
of €996,104 per infection averted and €88,692 
per quality-adjusted life-year (QALY) saved. Cost-effectiveness
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TABLE 12  Summary of the external validity of the cost-effectiveness studies 
Quality criteria
Pinkerton et al. 
199822
Pinkerton et al. 
200423
Pinkerton et al. 
200424
Herida et al. 
200625
Patient group – are the patients 
in the study similar to those of 
interest in England and Wales?
Unclear  Unclear Unclear Unclear
Health-care system/setting 
– comparability to England 
and Wales; comparability of 
available alternatives; similar 
levels of resources; institutional 
arrangements comparable?
No No No No
Treatment – comparability with 
clinical management?
Unclear Unclear Unclear Unclear
Resource costs – comparability 
between study and setting/
population of interest?
No No No No
TABLE 13  Base-case cost–utility ratios for men who have sex with men
Type of 
exposure
Probability 
PEP effective
HIV 
transmission 
probability
Probability 
source is HIV 
positive
Estimated or 
actual PEP 
compliance Cost per QALY Study
Unprotected 
receptive 
anal 
intercourse
0.80 0.02 1.00 0.83 –€22,141 Herida  et 
al. 200625
0.80 0.02 0.14 0.74 €31,862 Herida  et 
al. 200625
0.81 0.02 0.293 1.00a Cost saving (actual 
cost per QALY not 
reported)
Pinkerton et 
al. 200423
0.81 0.02 Not reported 0.778 US$ < 0 (actual 
figure not 
reported)
Pinkerton et 
al. 200424
0.79 0.02 0.18 0.69 US$6354 Pinkerton et 
al. 199822
Unprotected 
insertive anal 
intercourse
0.80 0.0006 1.00 0.83 €241,716 Herida  et 
al. 200625
0.80 0.0006 0.14 0.80 €1,952,497 Herida  et 
al. 200625
0.81 0.0006 0.293 1.00a US$686,525 Pinkerton et 
al. 200423
0.81 0.0006 Not reported 0.778 US$554,814 Pinkerton et 
al. 200424
0.79 0.0006 0.18 0.69 US$773,785 Pinkerton et 
al. 199822
All 
exposures 
combinedb
US$8607 Pinkerton et 
al. 200423
US$4907 Pinkerton et 
al. 200424
QALY, quality-adjusted life-year.
a  PEP was assumed to be effective only if the patient was known to have completed the regimen; otherwise effectiveness 
was set to 0.
b  Receptive or insertive anal intercourse, receptive oral sex and ‘other’.
References for sources of data can be found in the individual papers.22–25© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 14  Base-case cost–utility ratios for heterosexuals
Type of 
exposure
Probability PEP 
effective
HIV 
transmission 
probability
Probability 
source is 
HIV positive
Estimated or 
actual PEP 
compliance Cost per QALY Study
Unprotected 
receptive 
anal 
intercourse
0.80 0.02 1.00 0.81 –€22,031 Herida  et al. 
200625
0.80 0.02 0.005 0.60 €1,943,685 Herida  et al. 
200625
0.81 0.02 0.041 1.00a US$165,289 Pinkerton et 
al. 200423
0.81 0.02 Not reported 0.778 US$ < 0 (actual 
figure not 
reported)
Pinkerton et 
al. 200424
0.79 0.02 0.18 0.69 US$6354 Pinkerton et 
al. 199822
Unprotected 
receptive 
vaginal 
intercourse
0.80 0.001 1.00 0.81 €135,111 Herida  et al. 
200625
0.80 0.001 0.005 0.62 €38,653,452 Herida  et al. 
200625
0.81 0.001 0.041 1.00a US$262,562 Pinkerton et 
al. 200423
0.81 0.001 Not reported 0.778 US$380,891 Pinkerton et 
al. 200424
0.79 0.001 0.02 0.69 US$4,254,916 Pinkerton et 
al. 199822
All 
exposures 
combined: 
heterosexual 
femalesb
US$161,114 Pinkerton et 
al. 200424
All 
exposures 
combined: 
heterosexual 
malesc
US$685,560 Pinkerton et 
al. 200424
QALY, quality-adjusted life-year.
a  PEP was assumed to be effective only if the patient was known to have completed the regimen; otherwise effectiveness 
was set to 0.
b  Male–female receptive anal intercourse, male–female receptive vaginal intercourse.
c  Male–female insertive anal intercourse, male–female insertive vaginal intercourse, male–female other sexual exposure.
TABLE 15  Base-case cost–utility ratios for intravenous drug users (IDUs)
Type of 
exposure
Probability PEP 
effective
HIV 
transmission 
probability
Probability 
source is HIV 
positive
Estimated or 
actual PEP 
compliance
Cost per 
QALY Study
IDU 0.80 0.0067 1.00 0.61 –€1141 Herida  et 
al. 200625
0.81 0.003 0.214 1.00 US$86,462 Pinkerton et 
al. 200423
0.81 0.003 Not reported 0.778 US$97,867 Pinkerton et 
al. 200424
QALY, quality-adjusted life-year.Cost-effectiveness
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However, the authors report major differences in 
the cost-effectiveness ratio according to the type 
of exposure. PEP after receptive anal intercourse 
with an HIV-infected individual (men –€22,141, 
women –€22,031 per QALY saved) and PEP to an 
intravenous drug user (IDU) after sharing a needle 
with an HIV-infected person (–€1141 per QALY 
saved) were cost saving. PEP was cost-effective 
for MSM having receptive anal intercourse with 
a partner of unknown status (€31,862 per QALY 
saved). PEP was not considered cost-effective 
(cost per QALY €50,000) for all other exposures 
considered in the analysis.
One-way sensitivity analyses were performed on 
the compliance and life expectancy of HIV-infected 
individuals in this study.25 PEP after receptive 
anal intercourse with an HIV-infected individual 
remained cost saving (–€17,778 and –€18,860 per 
QALY saved for MSM and heterosexual women 
respectively). PEP to an IDU after needle sharing 
with an HIV-infected person remained cost-
effective but was no longer cost saving (€18,445 
per QALY saved). Further sensitivity analyses 
incorporating higher lifetime HIV costs resulting 
from longer survival resulted in the three exposure 
risks with negative ratios in the base case remaining 
cost saving but with higher cost ratios.
Herida and colleagues25 also performed threshold 
analyses for exposures with cost-effectiveness 
ratios under €200,000 per QALY saved, using 
minimum values of prevalence, per-contact HIV 
transmission or compliance required to achieve 
the cost-saving threshold (€0 per QALY saved) or 
the cost-effective threshold (€50,000 per QALY 
saved). The authors reported that PEP for MSM 
after receptive anal intercourse with a partner of 
unknown HIV status was cost saving for a per-
contact transmission risk of at least equal to 0.0411 
or an HIV prevalence of at least 0.208. For needle 
sharing with an individual of unknown serostatus 
the authors reported that cost-effectiveness 
occurred with a compliance of ≥ 0.92 with both 
the highest values of prevalence (0.21) and of the 
per-contact transmission risk (0.0092). The cost-
effectiveness ratio was reached for a per-contact 
transmission risk equal to 0.0208 for receptive 
vaginal intercourse with an HIV-infected partner.
Pinkerton and colleagues’23 cost–utility analysis 
of a PEP programme for 401 participants with 
possible non-occupational exposure to HIV found 
that the use of PEP prevented an estimated 1.59 
HIV infections (1.26 infections after adjusting for 
continuing risk behaviours over the subsequent 
10 years), with an overall cost–utility ratio of 
US$14,449 per QALY saved. In total, 96% of 
averted infections were among men who reported 
exposure through receptive anal intercourse with 
other men.
The authors report that the PEP programme was 
cost saving amongst men who have receptive anal 
intercourse with other men, and when the partner 
was known to be HIV positive.23 The overall 
cost–utility ratio for men reporting exposure 
through male–male sex (receptive or insertive 
anal intercourse, receptive oral intercourse or 
‘other’) was US$8607 per QALY saved, whereas the 
cost–utility ratio for all other exposures combined 
was US$258,667 per QALY saved. The cost per 
QALY saved for exposure by injecting drugs and 
male–female receptive anal sex was US$86,462 and 
US$165,289 respectively.
The results of the sensitivity analyses reported 
by the authors suggest that the PEP programme 
remained cost-effective when the effectiveness of 
PEP was set as low as 48% (base case 81%) and as 
long as PEP completion rates were greater than 
29%.23 The programme also remained cost-effective 
regardless of the percentage of partners known to 
be infected with HIV or the prevalence of infection 
among partners whose HIV status was unknown.
The cost–utility ratio was most sensitive to 
the receptive anal intercourse transmission 
probability.23 The authors report that the PEP 
programme would be cost saving overall if this 
probability exceeded 0.033 and would be cost-
effective (defined by the authors as a cost–utility 
ratio of US$60,000 per QALY saved) for 
probabilities as small as 0.009 (the base case was set 
at 0.02).
The Pinkerton and colleagues study24 of PEP in 96 
metropolitan statistical areas in the US estimated 
the respective mean and median cost–utility ratios 
to be US$15,728 and US$15,367 per QALY saved, 
with 63.9 HIV infections averted. PEP was cost 
saving for male–male and male–female receptive 
anal intercourse exposures (see Tables 13–15). Cost–
utility ratios for needle sharing and needlestick 
exposures were US$97,867 and $159,686 per 
QALY saved respectively. The cost–utility ratio 
exceeded $380,000 per QALY saved for all other 
types of exposure.
The authors report24 that the sensitivity analysis 
suggests that the results are moderately sensitive 
to PEP effectiveness and somewhat sensitive to the © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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proportion of people completing the PEP regimen, 
the proportion of PEP clients with known infected 
source partners and the lifetime costs of medical 
care and lost QALYs associated with a case of HIV 
infection.
The authors24 conclude that PEP is only cost-
effective in limited circumstances such as following 
receptive anal intercourse with a partner at high 
risk of infection and possibly following other high-
risk exposures with a partner known to be infected. 
The authors state that PEP was highly cost-effective 
for MSM, less cost-effective for IDUs and high-risk 
women, and probably not cost-effective for general 
population exposures or heterosexual men.24
The study by Pinkerton and colleagues22 evaluating 
the cost-effectiveness of PEP for a hypothetical 
cohort of 10,000 patients reporting sexual 
intercourse with a partner of unknown HIV status 
estimated that 19.62 HIV infections would be 
averted following receptive anal intercourse, 0.59 
following insertive anal intercourse, 0.11 following 
receptive vaginal intercourse and 0.07 following 
insertive vaginal intercourse.
In this study22 the base-case analysis suggested 
that PEP is only cost-effective for receptive anal 
intercourse (all other cost–utility ratios exceeded 
US$750,000 per QALY saved). The cost–utility 
ratio following receptive anal intercourse among 
MSM was US$6354 per QALY saved. This became 
cost saving if the probability that the source partner 
was HIV positive was greater than 0.25 (see Tables 
13–15).
The sensitivity analysis reported by Pinkerton and 
colleagues22 showed that PEP following receptive 
anal intercourse was always cost-effective across a 
range of values. PEP following receptive vaginal 
intercourse became cost-effective when the 
probability that the source partner was HIV positive 
was at least 0.73. The authors report that triple 
therapy was unlikely to be cost-effective relative to 
double therapy as the additional drug costs were 
not offset by treatment savings. The results did not 
appear to be sensitive to repeated exposure to HIV 
and PEP.22
Economic evaluation
One of the aims of the current report was to draw 
together the best available evidence to estimate 
the cost-effectiveness of non-occupational PEP 
for HIV in a UK setting. The current authors 
explored the feasibility of developing a de novo 
economic model, either by adapting an existing 
cost-effectiveness model or by constructing a new 
one. However, the available data to inform any 
cost-effectiveness analysis are very sparse, making 
it inappropriate to model the cost-effectiveness 
of non-occupational PEP for HIV at the present 
time. The limitation in the extent of the evidence 
for the clinical effectiveness of non-occupational 
PEP for HIV is the main reason for arriving at 
this conclusion, that is, the effectiveness of non-
occupational PEP is unknown. Only one study 
met the systematic review criteria for assessing 
the clinical effectiveness of non-occupational PEP, 
and the authors state that the study design and 
relatively small number of seroconversions do not 
allow conclusions about the effectiveness of PEP 
in preventing infection. In addition, there were 
limited data for other model parameters, such as 
per-exposure transmission probabilities, prevalence 
of HIV among different population groups and 
treatment compliance. Any modelling using such 
data inputs will be of limited value.
However, should better quality and more relevant 
data become available, the modelling frameworks 
presented by Pinkerton and colleagues23 and 
Herida and colleagues25 may be useful starting 
points for cost-effectiveness analysis. Although 
these studies should be viewed with caution, 
because the clinical effectiveness was informed from 
one study of the use of PEP in an occupational 
setting and was based on assumptions that the 
same conditions exist in a non-occupational setting, 
they have been conducted in an appropriate way 
and appear to have internal validity in terms of 
model structure. Any model should incorporate 
PEP adverse events and completion rates as these 
have important economic consequences.
Summary of cost-
effectiveness of PEP 
for non-occupational 
exposure to HIV
Four economic evaluations met the inclusion  •	
criteria of the review.
The methodological quality of the four studies  •	
is mixed. Each had a well-defined question, 
stated a reasonable study type and perspective 
and undertook a clear sensitivity analysis. 
However, each of the studies is constrained 
by a lack of published data on the clinical 
effectiveness of PEP after non-occupational Cost-effectiveness
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exposure, the per-exposure transmission 
risk, the compliance with medication and the 
prevalence of HIV infection amongst different 
population subgroups.
In addition, external validity appears to  •	
be poor. None of the studies was clearly 
generalisable to the UK. Lack of detailed 
information on the PEP regimes used in all 
of the studies prevented comparison with 
UK clinical management, as did the lack of 
information on study participants.
Results from the included studies suggest that  •	
PEP following non-occupational exposure to 
HIV is cost saving for:
men who have unprotected receptive anal    –
intercourse with men, whether the source 
partner is known to be HIV positive or not
heterosexuals  after  unprotected  receptive    –
anal intercourse
intravenous  drug  users  sharing  a  needle    –
with a known HIV-positive person.
PEP following non-occupational exposure  •	
to HIV was cost-effective for all male–male 
intercourse (unprotected receptive and 
insertive anal intercourse, unprotected 
receptive oral sex and ‘other’).
PEP following non-occupational exposure to  •	
HIV was possibly cost-effective for intravenous 
drug users and high-risk women.
In general, sensitivity analyses did not greatly  •	
alter the base-case findings. Some sensitivity to 
the following parameters was noted:
transmission probability following receptive    –
anal intercourse
effectiveness of PEP   –
proportion of clients completing PEP   –
proportion  of  clients  with  known  HIV-   –
positive partners
lifetime costs of treatment and number of    –
lost QALYs
receptive vaginal intercourse (which became    –
cost-effective) when  the  probability  of  the 
source  partner  being  HIV  positive  was 
≥ 0.73.
In summary, although the results of the  •	
studies are consistent and suggest that non-
occupational PEP may be cost-effective, the 
results should be treated with caution. It may 
not be appropriate to make assumptions that 
the same conditions exist in a non-occupational 
setting as in an occupational setting. The 
generalisibility to the UK of studies conducted 
in the US and France is not clear. Although 
transmission risks for specific sexual practices 
are likely to be the same, sexual behaviour and 
HIV incidence may not be similar and local 
costs may be different.
Because of limited data, especially on the  •	
effectiveness of non-occupational PEP for HIV, 
no de novo economic evaluation was conducted 
in the present study.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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F
our additional studies were identified that 
report data on adverse events and they are 
presented here to provide further information on 
this issue. Two comparative studies28,29 consider 
different non-occupational PEP interventions and 
two prospective observational studies30,31 in relevant 
populations report data on toxicity and completion 
of medication. Details of the four studies are shown 
below (Table 16). Study results are presented in 
Tables 17 and 18.
In one prospective comparative study28 of sexual 
assault victims who sought treatment within 
72 hours of sexual exposure, participants were 
assigned to either medium or high severity groups 
according to factors that could influence HIV 
transmission. Those in the medium severity group 
(n = 141) were given zidovudine plus lamivudine 
and those in the high severity group (n = 137) 
were given zidovudine plus lamivudine plus 
protease inhibitor. Follow-up was at 6 months and 
toxicity and compliance are reported. In the other 
comparative study29 PEP was provided within 72 
hours to individuals with exposures from partners 
known to have been or to be at risk for HIV 
infection through sexual exposure or injecting 
drug use. In total, 97% of participants were 
treated exclusively with dual reverse transcriptase 
inhibitors. Rates of completion of PEP and 
toxicities after 4 weeks are reported.29
In one 18-month prospective observational study30 
sexual assault survivors attending one of 24 Sexual 
Assault Treatment Centres (SATCs) within 72 hours 
of the assault were offered PEP if considered to 
be at high or unknown risk of HIV infection. The 
primary outcomes in this study were acceptance 
and completion rate, and adverse events were 
also reported. All participants were prescribed 
Combivir (zidovudine + lamivudine) and Kaletra 
(lopinavir + ritonavir) and received counselling 
regarding dosing, adherence and adverse events. 
Follow-up visits were scheduled for days 2–4 and 
weeks 1, 2, 3 and 4. The second prospective 
observational study31 enrolled patients presenting 
after sexual exposure to HIV from source partners 
known to be, or suspected of being, infected with 
HIV. The participants were prescribed zidovudine 
plus lamivudine if reporting the exposure within 72 
hours and also received risk reduction counselling. 
Chapter 6  
Adverse events
Follow-up visits were scheduled for weeks 1, 2, 
4, 6, 12 and 26. The primary outcomes for this 
study were enrolment into concurrent behavioural 
risk reduction interventions, demand for non-
occupational PEP and characteristics of those 
treated. Completion and adverse events were also 
reported.
All of the studies have methodological limitations 
in that, although there were objective criteria 
for the eligibility of subjects, subjects were self-
referring and there was non-blinded assessment 
of self-reported outcomes. Not all outcomes are 
reported separately for all treatment groups in the 
comparative studies and it is not clear whether the 
different groups within each study are comparable; 
participants were also allowed to switch between 
treatment groups. The observational studies are 
limited by the lack of control groups. Although all 
of the sexual assault survivors attending SATCs 
were offered PEP,30 25.9% of health-care providers 
prescribing PEP reported strongly encouraging 
or encouraging participants to accept and 3.1% 
reported strongly discouraging or discouraging 
acceptance, which could affect both acceptance 
and possibly completion. Selected outcomes were 
reported separately for the high-risk and unknown-
risk groups.30 The recruitment by Shoptaw and 
colleagues31 focused on an underserved area 
and participants then self-referred to the study, 
meaning that the generalisability of the study 
findings is unclear.
Completion of treatment
Completion of treatment rates in the four studies 
are shown in Table 17. Garcia and colleagues28 
found that participants who received dual therapy 
were more likely to complete PEP (68%) than 
those who received three drugs (53%) (p = 0.01). 
In the high severity group 21% interrupted the 
use of protease inhibitor and completed PEP with 
two drugs, with the main reason for interruption 
being toxicity. Compliance at 6 months of follow-
up was similar in both the medium and the high 
severity groups [odds ratio (OR) 1.0, 95% CI 
0.8–1.3].28 In the San Francisco PEP study,29 over 
all groups, 78% of participants completed 4 weeks 
of treatment. Significantly more patients treated Adverse events
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TABLE 16  Studies reporting adverse event/compliance data
Study Population Interventions
Garcia et al. 200528
Brazil
Prospective cohort study
Sexual assault victims 
Medium-risk group (n = 141) (vaginal/oral intercourse 
with ejaculation but without trauma) 
ZDV + 3TC
High-risk group (n = 137) [anal penetration; vaginal 
exposure with genital trauma; exposure to many 
aggressors; presence of factors that increase risk 
(inflammation, ulcers, bleeding, trauma, laceration, 
menstruation); aggressor known to be HIV positive]
ZDV + 3TC + PI
All patients offered psychological and supportive 
counselling
Kahn et al. 200129
San Francisco
PEP study
Sexual or injecting drug use exposure 
Source HIV status/ART history unknown (n = 351) ZDV + 3TC (combined pill twice daily)
As above with source plasma HIV RNA levels on 
treatment above the limits of detection (n = 8)
ZDV + 3TC + Nfv (combined pill twice 
daily + Nfv three times daily)
Source receiving or participant refused ZDV (n = 31) ddI + d4T (two pills twice daily)
As above with source plasma HIV RNA levels on 
treatment above the limits of detection (n = 5)
ddI + d4T + Nfv (two pills twice 
daily + Nfv three times daily)
If source was receiving Nfv and had detectable plasma 
HIV RNA levels, alternative to Nfv given (n = 2)
Other ART
All groups received risk reduction counselling and 
medication adherence counselling
Loutfy et al. 200830
Canada
Prospective observational 
study 
Sexual assault survivors (n = 798): 69 high risk; 729 
unknown risk 
Combivir (ZDV + 3TC) (one pill twice 
daily) and Kaletra (lopinavir/ritonavir) 
(three capsules orally twice a day) for 
28 days
Counselling regarding dosing, the importance of 
adherence and adverse events was provided
Shoptaw et al. 200831
US
Prospective observational 
study
Patients presenting post sexual exposure to persons 
known or suspected to be infected with HIV (n = 100)
ZDV + 3TC (twice daily)
Risk reduction counselling provided
3TC, lamivudine; ART, antiretroviral therapy; d4T, stavudine; ddI, didanosine; Nfv, nelfinavir; PI, protease inhibitor (indinavir 
or nelfinavir); RNA, ribonucleic acid; ZDV, zidovudine.
with didanosine plus stavudine completed 4 weeks 
of therapy than did those receiving zidovudine 
plus lamivudine (94% versus 76%, p = 0.01). 
However, the higher rates of completion seen 
in participants using didanosine plus stavudine 
may have been due to the study protocol. This 
discouraged participants from changing to 
zidovudine plus lamivudine if they developed 
tolerable adverse events, in an attempt to provide 
treatment against a possibly resistant strain. In 
contrast, those taking zidovudine plus lamivudine 
who experienced adverse events were encouraged 
to switch to didanosine plus stavudine to complete 
their treatment course. Among participants who 
completed 4 weeks of therapy, the percentage of 
participants reporting complete adherence during © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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TABLE 17  Assessment of completion of treatment 
Study Compliance Intervention
Garcia et al. 
200528
Medium severity group (dual 
therapy, n = 141)
High severity group (triple 
therapy, n = 137)
Completed 6 months of follow-up 
and 28 days of PEP , n (%)
69 (48.9) 53 (38.7)
Completed 6 months of follow-up, 
interruption of PEP , n (%)
11 (7.8) 23 (16.8)
Abandoned follow-up but 
completed 28 days of PEP , n (%)
27 (19.2) 20 (14.6)
Abandoned follow-up and 28 days 
of PEP , n (%)
34 (24.1) 41 (30)
Total, n (%) 141 (100) 137 (100)
Kahn et al. 
200129
ZDV + 3TC 
(n = 351)
ZDV + 3TC + Nfv 
(n = 8)
ddI + d4T 
(n = 31)
ddI + d4T + Nfv 
(n = 5)
Completed 4 weeks of assigned 
PEP , n (%)
267 (76) 6 (75) 29 (94) 5 (100)
Completed 4 weeks but changed 
initial PEP , n (%)
3 (1) 0 0 0
Discontinued PEP , n (%) 47 (13) 0 1 (< 1) 0
  Toxicity, n (%) 27 (8) – 0 –
  Source not infected, n (%) 10 (3) – 0 –
  Participant preference, n (%) 6 (2) – 1 (< 1) –
  Participant HIV infected, n (%) 4 (1) – 0 –
Loutfy et al. 
200830
n = 798
Non-adherent (%) 76.0 high-risk group
66.7 unknown-risk group
28-day course completed (%) 23.9 high-risk group
33.2 unknown-risk group
Shoptaw et 
al. 200831
n = 100
Non-adherent (%) 36
28-day course completed (%) 64
3TC, lamivudine; d4T, stavudine; ddI, didanosine; Nfv, nelfinavir; ZDV, zidovudine.
the 4 days before the clinic visit ranged from 78% 
to 84%.29
The percentage of participants receiving Combivir 
and Kaletra who completed the course of PEP 
was 23.9% in the high-risk group and 33.2% in 
the unknown-risk group in the study of sexual 
assault survivors by Loutfy and colleagues.30 This 
study found that health-care provider-perceived 
moderate or high participant anxiety at the 
initial visit, assault by a stranger or an assailant 
known to the participant less than 24 hours 
previously or absence of concomitant physical 
assault were predictors of completion. Reasons for 
discontinuation included adverse events (81.2%), 
interference with usual routine (42%), inability 
to take time away from work, school or other 
commitments (21.7%) and reassessment of HIV risk 
(18.8%). In the study by Shoptaw and colleagues31 
86% of participants were dispensed the full 28-day 
supply of PEP and 64% of participants receiving 
zidovudine plus lamivudine completed treatment.
Assessment of toxicity
Toxicity results are shown in Table 18. In one 
study28 93% of the participants receiving three 
drugs reported at least one side effect, compared 
with 66% of the participants receiving two drugs 
(p < 0.01). Digestive discomfort was the most 
common side effect and was statistically more Adverse events
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TABLE 18  Assessment of toxicity
Study Side effect
Garcia et al. 
200528
Medium severity group 
(dual therapy, n = 141)
High severity group (triple 
therapy, n = 137)
p-value
Any referred intolerance, n (%) 76 (66) 106 (93) p < 0.01
Digestive intolerance, n (%) 70 (60) 101 (89) p  < 0.01
  Nausea, n (%) 62 (53) 93 (82) p < 0.01
  Vomiting, n (%) 23 (20) 55 (48) p < 0.01
  Dyspepsia, n (%) 20 (17) 40 (35) p  < 0.01
Malaise, n (%) 26 (12) 60 (53) p < 0.01
  Headache, n (%) 14 (12) 19 (17) p = 0.35
  Fever, n (%) – 6 (5) p = 0.01
  Asthenia, n (%) 4 (3) 13 (11) p = 0.02
  Dizziness, n (%) 7 (6) 20 (18) p < 0.01
  Myalgia, n (%) 2 (2) 5 (4) p = 0.28
Cutaneous rash, n (%) 3 (3) 16 (14) p < 0.01
Nephrolithiasis, n (%) – 9 (8) p < 0.01
Laboratorial abnormalities, n (%) 18 (16) 39 (33) p < 0.01
Premature interruption of PEP (all 
drugs), n (%)
12 (10) 35 (29) p < 0.01
Kahn et al. 
200129
n = 396
Adverse events experienced: Combined treatment groups
Nausea 52%
Fatigue 44%
Headache 24%
Diarrhoea 15%
Anorexia 12%
Loutfy et al. 
200830
n = 798
Adverse events resulting in drug 
discontinuation, n
3
Participants reporting at least one 
adverse event, any grade, n (%)
265 (96.4)
Participants reporting at least one 
adverse event grade 2–4 (median 3, 
range 1–8), n (%)
212 (77.1)
Adverse events experienced:
Fatigue 58.5%
Nausea 49.5%
Diarrhoea 22.5%
Headache 20.7%
Mood changes 20.7%
Vomiting 20.4%
Stomach problems 16.4%
common in participants who received three 
drugs (p < 0.01).28 Severe side effects were seen in 
patients receiving three drugs and hospitalisation 
occurred in six cases, as a result of Stevens–
Johnson syndrome (n = 1), nephrolithiasis (n = 2) 
and severe gastrointestinal symptoms (n = 3).28 In 
the San Francisco study29 subjective toxicity for 
all study groups included nausea (52%), fatigue 
(44%), headache (24%), diarrhoea (15%) and 
anorexia (12%). Toxicity was the main reason for 
discontinuing treatment (n = 27, 8%).29© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Study Side effect
Shoptaw et 
al. 200831
n = 100
Participants reporting at least one 
adverse event, n (%)
79 (79)
Adverse events experienced:
Fatigue 48%
Nausea 45%
Diarrhoea 7%
Headache 20%
Stomach problems 11%
Malaise 8%
Insomnia 6%
Difficulty in concentrating 4%
Depression 4%
TABLE 18  Assessment of toxicity (continued)
The most common adverse events experienced 
in both observational studies were also fatigue 
(58.5%30 and 48%31) and nausea (49.5%30 and 
45%31). Loutfy and colleagues30 report that the 
majority of sexual assault survivors (77.1%) 
reported at least one adverse event (median 3, 
range 1–8) of grade 2–4 severity [adverse events 
were graded 1–4 using the US National Institute 
of Allergy and Infectious Diseases standardised 
toxicity grading system (grade 4 most severe)]. 
Three participants discontinued PEP because 
of adverse events, but no further details were 
given. The authors reported that participants who 
experienced vomiting were less likely to complete 
PEP than those who did not (OR 0.27, 95% CI 
0.12–0.6, p = 0.0007).30 Shoptaw and colleagues31 
describe one participant requiring hospitalisation 
for suicide ideation, but this was not thought to be 
as a result of the study medication.
Summary of adverse events 
of PEP for non-occupational 
exposure to HIV
There is limited evidence in terms of quantity  •	
and quality, with two comparative studies and 
two prospective observational studies reporting 
adverse events and/or treatment completion 
rates for non-occupational PEP for HIV.
One comparative study reported a significantly  •	
higher degree of toxicity and therapy 
discontinuation among sexual assault victims 
taking a three-drug regimen compared with 
those taking a two-drug therapy. Digestive 
discomfort was the most common side effect 
and was significantly higher in participants 
who received three drugs. PEP therapy was 
completed by 68% of participants receiving 
dual therapy and 53% of those receiving triple 
therapy.
A second comparative study reported  •	
statistically higher completion rates among 
participants taking didanosine plus stavudine 
compared with those taking zidovudine plus 
lamivudine, although this may have been due 
to the study protocol. Complete adherence at 
4 weeks was 78% overall, ranging from 40% to 
79% for different drug combinations. Toxicity 
was the main reason for discontinuation of 
treatment, with nausea and fatigue being the 
most common side effects.
One prospective observational study reported  •	
low completion of treatment rates, with 23.9% 
in the high-risk group and 33.2% in the 
unknown-risk group completing the course 
of PEP. The most common adverse events 
experienced by the participants were fatigue 
and nausea.
A second prospective observational study also  •	
found that fatigue and nausea were the most 
commonly experienced adverse events and 
that the majority of participants experienced 
adverse events. PEP therapy was completed by 
64% of participants.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Statement of 
principal findings
Clinical effectiveness
One cohort study21 met the inclusion criteria for 
the review of clinical effectiveness.
This study had methodological limitations and 
limitations in the quality of the reporting: it was 
unclear how the sample was selected, whether the 
sample size was adequate and whether the study 
is generalisable beyond the specific cohort among 
which it was conducted. Dropouts are reported 
but are not included in the analysis and there is 
no blind assessment of outcomes. The authors do 
report objective eligibility criteria and the groups 
are comparable at baseline.
The study reported seroconversion to HIV, drug 
use and risk behaviours in a group receiving non-
occupational PEP for HIV. The participants in 
the study were a Brazilian cohort of 200 high-risk 
MSM.
Seroincidence in the cohort as a whole (2.9 per 100 
person-years) was very similar to that expected by 
the study authors in this population (3.1 per 100 
person-years, p > 0.97), despite the seroconversion 
to HIV being 1 out of 68 in the PEP group and 
10 out of 132 in the group not receiving PEP. 
The study reported that, on average, high-risk 
sexual activities declined over time for both PEP 
and non-PEP users. The study authors concluded 
that a public health PEP programme would not 
have a major impact on HIV transmission in this 
population.
Cost-effectiveness
Four studies22–25 met the inclusion criteria for the 
review of cost-effectiveness.
The methodological quality of the cost-effectiveness 
studies was mixed, with each employing well-
defined questions, the appropriate perspective, 
appropriate methods of analysis and clear 
sensitivity analyses. Each study is, however, limited 
by the unknown effectiveness of the intervention, 
both the dual/triple drug regimen and the use of 
PEP in a non-occupational exposure patient group.
All four studies evaluated 28 days of PEP post 
non-occupational exposure to HIV, but full details 
are not given. Two of the studies considered 
hypothetical cohorts.22,24
Results from the studies suggest that PEP following 
non-occupational exposure to HIV is cost saving 
for men who have unprotected receptive anal 
intercourse with men, whether the source partner 
is known to be HIV positive or not; heterosexuals 
after unprotected receptive anal intercourse; and 
intravenous drug users sharing needles with a 
known HIV-positive person.
PEP following non-occupational exposure to HIV 
was cost-effective for all male–male intercourse 
(unprotected receptive and insertive anal 
intercourse, unprotected receptive oral sex and 
‘other’). PEP following non-occupational exposure 
to HIV was possibly cost-effective for intravenous 
drug users and high-risk women.
In general, sensitivity analyses did not greatly alter 
the base-case findings.
In summary, although the results of the studies 
are consistent and suggest that non-occupational 
PEP may be cost-effective, the results should be 
treated with caution. It may not be appropriate to 
make assumptions that the same conditions exist 
in a non-occupational setting as in an occupational 
setting and the generalisibility to the UK of studies 
conducted in the US and France is questionable as 
sexual behaviour and HIV incidence may not be 
similar.
Adverse events
Additional studies were sought to supply further 
information on adverse events. The evidence 
was limited in terms of quantity and quality, with 
two comparative studies and two observational 
studies reporting adverse events and/or treatment 
completion rates for non-occupational PEP.
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One comparative study28 reported a significantly 
higher degree of toxicity and therapy 
discontinuation among rape victims taking a 
three-drug regimen compared with those taking 
a two-drug regimen. Completion of PEP therapy 
was low in both dual and triple therapy. A second 
comparative study29 reported statistically higher 
completion rates among participants taking 
didanosine plus stavudine compared with those 
taking zidovudine plus lamivudine, although this 
may have been due to the study protocol.
One prospective observational study reported low 
rates of completion of treatment, with 23.9% in 
the high-risk group and 33.2% in the unknown-
risk group completing the course of PEP. The 
most common adverse events experienced by the 
participants were fatigue and nausea.30 A second 
prospective observational study31 also found that 
fatigue and nausea were the most commonly 
experienced adverse events and that the majority 
of participants experienced adverse events. PEP 
therapy was completed by 64% of participants.
Strengths and limitations 
of the assessment
The review has certain strengths:
It is independent of any vested interest. •	
The review brings together the evidence  •	
for the clinical effectiveness and the cost-
effectiveness of non-occupational PEP for HIV 
and adverse event data by applying consistent 
methods of critical appraisal, presentation and 
transparency.
The review was guided by the principles  •	
of undertaking a systematic review. Before 
undertaking the review the methods were set 
out in a research protocol (Appendix 1) and 
this was commented on by an advisory group. 
The protocol defined the research question, 
inclusion criteria, quality criteria, data 
extraction process and methods employed to 
undertake the different stages of the review.
An advisory group has informed the review  •	
from its initiation, through the development 
of the research protocol and completion of the 
report.
In contrast, there were certain limitations placed 
upon the review:
The number and type of studies available for  •	
inclusion in the review was limited. No RCTs 
were identified and the economic evaluations 
were not conducted in the UK.
Synthesis of the included studies was through  •	
narrative review. Because of the limitations of 
the literature, meta-analysis was not possible.
Time and resource constraints for this short  •	
report together with the lack of effectiveness 
data for the use of non-occupational PEP 
for HIV prevented the development of an 
economic evaluation and so the assessment of 
cost-effectiveness was limited to a systematic 
review of existing cost-effectiveness studies.
Other relevant issues
Only one cohort study met the systematic  •	
review inclusion criteria for the assessment of 
the clinical effectiveness of non-occupational 
PEP for HIV. The study design and relatively 
small number of seroconversions do not allow 
conclusions to be made about the effectiveness 
of PEP in preventing infection. However, 
results suggest that PEP made no difference 
to the expected HIV seroconversion rate for a 
high-risk HIV-seronegative homosexual male 
cohort in Rio de Janeiro, Brazil.
One of the issues of concern is that PEP may  •	
be relied upon as a primary form of HIV 
prevention and will fail to reduce or may 
actually increase high-risk exposures because it 
is perceived to fully prevent virus transmission. 
In the included study PEP was not associated 
with an increase in reported high-risk 
behaviour. Reported high-risk behaviour 
declined slightly for the cohort as a whole but 
these results should be viewed with caution 
because of the potential for under-reporting of 
self-reported high-risk activities.
Various assumptions were made in the studies  •	
considering the cost-effectiveness of non-
occupational PEP for HIV. Of most concern is 
the use of the estimate of effectiveness from 
the occupational PEP setting, which is based 
on the assumption that the same conditions 
exist in the non-occupational setting as in the 
occupational setting.
Other assumptions are acknowledged in the  •	
studies. For example, in the study conducted 
in France25 compliance could only be estimated 
from the database for 47% of PEP prescriptions 
and so overall compliance was estimated at 
0.75. However, overestimation of compliance 
would improve the cost-effectiveness ratio. 
There were no available data for lifetime 
HIV/AIDS costs in France and so these were © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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estimated by the authors. The model did not 
take into account the possibility that some 
patients seeking PEP may continue at-risk 
behaviour. The study also did not consider 
PEP adverse events. The authors state that 
taking these into account would further reduce 
the cost-effectiveness ratio of the overall PEP 
programme. The number of HIV infections 
predicted by the model was higher than that 
actually seen; however, HIV serology 6 months 
after PEP initiation was only available for 18% 
of patients and so the authors suggest that the 
true number of PEP failures may be higher.
Pinkerton and colleagues •	 24 acknowledge that 
there are a number of issues of uncertainty 
in their study of non-occupational PEP in US 
metropolitan statistical areas. The results were 
most sensitive to the effectiveness of PEP and 
the per-exposure transmission probability for 
receptive anal intercourse. The lack of evidence 
of effectiveness of PEP for non-occupational 
exposures to HIV means that the results should 
be interpreted with caution. With regard to 
per-exposure transmission probabilities, the 
probabilities used in this study did not take into 
account variations in infectiousness over the 
course of HIV disease, interpersonal variability 
or potential reductions from the use of highly 
active antiretroviral therapy.
Pinkerton and colleagues conclude from  •	
their hypothetical cohort study22 that, from 
an economic effectiveness perspective, PEP 
should be restricted to partners of infected 
persons (e.g. serodiscordant couples), 
patients reporting unprotected receptive anal 
intercourse (including condom breakage) and 
possibly cases in which there is a substantial 
likelihood that the partner is infected.
Various uncertainties, such as HIV prevalence  •	
rates, per-exposure transmission rates, 
completion of treatment and the impact of 
the number of pills prescribed daily, HIV 
status of partner and incomplete suppression 
of virus, some of which may vary in different 
locales, must be considered when modelling 
cost-effectiveness. Also, the potential for PEP 
programmes to incorporate risk counselling 
and the opportunity for intensive prevention 
counselling at the time of medication with 
PEP to influence future exposures must also be 
considered.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Non-occupational 
PEP for HIV
It is not possible to draw conclusions on the clinical 
effectiveness of non-occupational PEP for HIV 
because of the limited evidence in terms of the 
quantity and quality of studies. Only one small 
cohort study was identified that met the inclusion 
criteria for the systematic review. Cost-effectiveness 
has been assessed in four economic evaluations 
using evidence on effectiveness taken from the 
use of PEP in the occupational setting. Results are 
consistent across studies and suggest that non-
occupational PEP may be cost-effective, especially 
in certain population subgroups. Although the 
studies have been conducted in an appropriate way 
and have internal validity in terms of the structure 
of the model and plausible results, the assumptions 
and data sources mean that the results should be 
treated with caution. The generalisibility to the 
UK of studies conducted in the US and France is 
not clear. Although transmission risks for specific 
sexual practices are likely to be the same, sexual 
behaviour and HIV incidence may not be similar 
and local costs may be different.
Research priorities
The most important research need is a comparative 
study to establish the effectiveness of using non-
occupational PEP compared with not using PEP, 
preferably within the UK using the currently 
recommended intervention. Data are also needed 
on HIV prevalence, seroconversion rates, per-
exposure transmission, adverse events, treatment 
compliance rates, viral resistance rates, high-risk 
behaviours and effects of intensive counselling in 
different population groups. Some of these issues 
will be addressed by the NONOPEP project, which 
is an MRC-funded surveillance programme of 
PEP for non-occupational exposure to HIV. The 
study aims to describe current PEP prescribing 
practices and the demographic and exposure 
characteristics of individuals presenting for PEP; 
to evaluate the problems associated with taking 
antiretroviral therapy such as adverse events; to 
assess whether seroconversion has occurred and 
within which groups; and to contribute to a wider 
European study on the efficacy of PEP in the non-
occupational setting. Data have been collected on 
individuals by means of a paper questionnaire, 
submitted to the Communicable Disease 
Surveillance Centre at baseline (presentation at 
clinic) and at three follow-up intervals (4 weeks, 
3 months and 6 months). This study is due for 
submission shortly. Although there are challenges 
in conducting this research because of factors 
such as self-referral and follow-up of participants 
and self-reported outcomes, data generated from 
this study will be useful for informing any future 
economic modelling of the cost-effectiveness of 
non-occupational PEP in the UK.
Chapter 8  
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T
he a priori methods used for the review are 
outlined below. The sources of information 
used are outlined in Appendix 2.
Study inclusion
Specific inclusion criteria will be defined. The 
full literature search results will be screened by 
one reviewer and checked by a second reviewer to 
identify all citations that may meet the inclusion 
criteria. Full manuscripts of all selected citations 
will be retrieved and assessed by two reviewers 
against the inclusion criteria. Disagreements over 
study inclusion will be resolved by consensus or if 
necessary by arbitration by a third reviewer.
The planned inclusion/exclusion criteria for the 
systematic review are as follows.
Population
Humans with non-occupational exposure to HIV. 
This may be by:
unprotected sexual exposure (oral, vaginal,  •	
anal), either voluntary or rape, with an HIV-
infected partner or partner of unknown HIV 
status
exposure to a needle contaminated by a known  •	
or potentially infected substance in a non-
occupational setting.
Intervention
Any antiretroviral drug regimen administered as 
PEP for a short period (28 days) to HIV-negative 
people potentially exposed to HIV through 
unprotected sexual contact or use of a potentially 
contaminated needle or potentially contaminated 
biological fluid.
Comparator
No intervention. •	
Group not receiving PEP. •	
A different PEP regimen. •	
Outcomes
HIV seroconversion frequency. •	
Adverse effects and complications of PEP. •	
Adherence to PEP. •	
Health-related quality of life. •	
Costs or some measure of cost-effectiveness. •	
Design
RCT, CCT, cohort study or case–control study. •	
Cost-effectiveness/utility studies. •	
Descriptive studies with no control group will  •	
be excluded.
Data extraction
The extraction of study findings will be conducted 
by two reviewers using a predesigned and piloted 
data extraction form to avoid any errors. Any 
disagreements between reviewers will be resolved 
by consensus or if necessary by arbitration by a 
third reviewer.
Quality assessment
The methodological quality of included studies will 
be assessed using formal tools specific to the design 
of the study and focusing on possible sources of 
bias. Quality assessment of RCTs will be conducted 
using criteria developed by the NHS Centre for 
Reviews and Dissemination; observational studies 
will be assessed using criteria developed by Spitzer 
et al.18 Quality assessment of economic evaluations 
will be conducted using a checklist adapted from 
those developed by Drummond and Jefferson19 and 
Philips et al.20 Study quality will be assessed by two 
reviewers. Any disagreements between reviewers 
will be resolved by consensus or if necessary by 
arbitration involving a third reviewer.
Data synthesis
The methods of data synthesis will be determined 
by the nature of the studies identified through 
searches and included in the review. Quantitative 
synthesis of results, for example meta-analysis, 
will be considered if there are several high-
quality studies of the same design and sources of 
heterogeneity will be investigated by subgroup 
analyses if applicable. The results of any included 
studies suitable for quantitative synthesis will also 
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be summarised in a narrative form along with a 
narrative synthesis of the results from studies for 
which quantitative synthesis is not possible. All 
results will also be tabulated.
Economic evaluation
When appropriate, and if time and resources allow, 
an economic model will be devised by adapting an 
existing cost-effectiveness model or constructing 
a new one using the best available evidence to 
determine cost-effectiveness in a UK setting. 
Data on resource use and costs will be taken from 
the published literature and from NHS sources 
when appropriate and available. The perspective 
of the economic analysis will be that of the NHS 
and Personal Social Services. Effectiveness data 
will be taken from published studies and used 
in conjunction with other relevant data (e.g. 
resource use, unit costs) to populate the model to 
obtain measures of cost-effectiveness. If available, 
quality of life information will be obtained from 
the literature or other sources to calculate cost–
utility estimates in terms of cost per QALY. The 
robustness of the results to the assumptions made 
in the model will be examined through sensitivity 
analysis and/or probabilistic sensitivity analysis.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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T
he following search strategy was used in Ovid 
MEDLINE(R) from 1950 to November Week 
2 2007 and adapted for other databases. Results 
were obtained for English language and non-
English language papers. Bibliographies of related 
papers were assessed for relevant studies. Tables 
19 and 20 outline the databases and issues/dates 
searched. Figures 1 and 2 provide flowcharts of the 
clinical effectiveness and cost-effectiveness studies 
respectively.
The search strategy used for non-occupational PEP 
was as follows:
exp HIV/ (59429) 1 
exp hiv-1/ (46463) 2 
exp hiv-2/ (3192) 3 
exp HIV Infections/ (169604) 4 
exp hiv antibodies/ (7992) 5 
(hiv or human immunodeficincy virus$).ti,ab.  6 
(140649)
exp Acquired Immunodeficiency Syndrome/  7 
(68119)
or/1–7 (214277) Population set 1 8 
(post?exposure prophylax$or PEP or nPEP or  9 
PEPSE).ti,ab. (4037)
post-exposure prophylax$.ti,ab. (475) 10 
post exposure prophylax$.ti,ab. (475) 11 
postexposure prophylax$.ti,ab. (483) 12 
or/9–12 (4402) Population set 2 13 
(highly active antiretroviral therapy or haart). 14 
ti,ab. (7126)
exp antiviral agents/ (210658) 15 
exp anti-retroviral agents/ (40013) 16 
exp anti-hiv agents/ (34216) 17 
exp hiv fusion inhibitors/ (438) 18 
exp hiv integrase inhibitors/ (470) 19 
exp hiv protease inhibitors/ (7818) 20 
(combivir or zidovudine or lamivudine or  21 
kaletra or lopinavir or ritonavir).ti,ab. (9741)
or/14–21 (215377) Intervention 1 set 1 22 
non?occupational.ti,ab. (506) 23 
nonoccupational.ti,ab. (506) 24 
non occupational.ti,ab. (671) 25 
or/23–25 (1169) Population set 3 26 
Occupational Exposure/ (28336) Population set  27 
4
8 and 13 (514) Combined population set 5 28 
28 and 22 (345) PEP population with  29 
intervention
29 not 27 (212) Non-occupational set 30 
limit 30 to (humans and english language)  31 
(182) Non-occupational set English language 
download A
30 not 31 (30) Non-occupational set non- 32 
English download B
29 not 30 (133) Occupational set all languages  33 
download C
from 31 keep 1–182 (182) 34 
from 32 keep 1–30 (30) 35 
from 33 keep 1–133 (133) 36 
The search strategies were translated to run in the 
databases listed above. Full search strategies are 
available upon request.
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TABLE 19  Clinical effectiveness and cost-effectiveness searches
Databases searched
Clinical effectiveness: issues or 
dates searched
Cost-effectiveness: issues or dates 
searched
Cochrane Library – CDSR Issue 4 2007; searched 13 September 
2007
Cochrane Library – CENTRAL Issue 4 2007
Ovid MEDLINE(R)  1950–November Week 2 2007 1950–November Week 2 2007
EMBASE  1980–2007 Week 49 1980–2007 Week 49
Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations 
12 December 2007 12 December 2007
DARE (Database of Abstracts of 
Reviews of Effectiveness)
12 December 2007
HTA database (on CRD databases) 12 December 2007
NRR (National Research Register)  12 December 2007
ClinicalTrials.gov (http://clinicaltrials.
gov/)
12 December 2007
NHS Economic Evaluations Database 
2005–2007
12 December 2007
TABLE 20  Adverse events searches
Databases  Years/dates searched
Ovid MEDLINE(R)  1996–September Week 3 2007; searched 2 October 2007
Ovid MEDLINE(R) In-Process & Other Non-Indexed 
Citations
28 September 2007
EMBASE  1996–2007 Week 38© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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FIGURE 2  Flowchart of cost-effectiveness studies.
Identified on searching
n = 379
Excluded
n = 361
Excluded
n = 17
Abstracts inspected
n = 379
Full papers inspected
n = 18
Papers for appraisal
and data extraction
n = 1
Identified on searching
n = 279
Excluded
n = 266
Excluded
n = 9
Abstracts inspected
n = 279
Full papers inspected
n = 13
Papers for appraisal
and data extraction
n = 4
FIGURE 1  Flowchart of clinical effectiveness studies.© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Clinical effectiveness studies
Bernasconi E, Jost J, Ledergerber B, Hirschel B, 
Francioli P, Sudre P. Antiretroviral prophylaxis for 
community exposure to the human immunodeficiency 
virus in Switzerland, 1997–2000. Swiss Med Wkly 
2001;131:433–7. (Questionnaire.)
Braitstein P, Chan K, Beardsell A, McLeod A, Montaner 
JS, O’Shaughnessy MV, et al. Prescribing practices in 
a population-based HIV postexposure prophylaxis 
program. AIDS 2002;16:1067–70. (No comparison group 
and prescribing practice as outcome.)
Luque A, Hulse S, Wang D, Shahzad U, Tanzman 
E, Antenozzi S, et al. Assessment of adverse events 
associated with antiretroviral regimens for postexposure 
prophylaxis for occupational and nonoccupational 
exposures to prevent transmission of human 
immunodeficiency virus. Infect Control Hosp Epidemiol 
2007;28:695–701. (Chart review.)
Martin JN, Roland ME, Neilands TB, Krone MR, 
Bamberger JD, Kohn RP, et al. Use of postexposure 
prophylaxis against HIV infection following sexual 
exposure does not lead to increases in high-risk behavior. 
AIDS 2004;18:787–92. (No comparison group.)
Meel BL. HIV/AIDS post-exposure prophylaxis (PEP) 
for victims of sexual assault in South Africa. Med Sci Law 
2005;45:219–24. (No comparison group.)
O’Sullivan BG, Levy MH, Dolan KA, Post JJ, Barton SG, 
Dwyer DE, et al. Hepatitis C transmission and HIV post-
exposure prophylaxis after needle- and syringe-sharing 
in Australian prisons. Med J Aust 2003;178:546–9. (Study 
design.)
Poynten IM, Smith DE, Cooper DA, Kaldor JM, Grulich 
AE. The public health impact of widespread availability 
of nonoccupational postexposure prophylaxis against 
HIV. HIV Med 2007;8:374–81. (No comparison group.)
Puro V, Soldani F, De Carli G, Lazarevic Z, Mattioli 
F, Ippolito G, et al. Drug-induced aminotransferase 
alterations during antiretroviral HIV post-exposure 
prophylaxis. AIDS 2003;17:1988–90. (Occupational 
exposure.)
Puro V, De Carli G, Orchi N, Palvarini L, Chiodera 
A, Fantoni M, et al. Short-term adverse effects from 
and discontinuation of antiretroviral post-exposure 
prophylaxis. J Biol Regul Homeost Agents 2001;15:238–42. 
(Includes health-care workers.)
Rabaud C, Bevilacqua S, Beguinot I, Dorvaux 
V, Schuhmacher H, May T, et al. Tolerability of 
postexposure prophylaxis with zidovudine, lamivudine, 
and nelfinavir for human immunodeficiency virus 
infection. Clin Infect Dis 2001;32:1494–5. (Included 
occupational exposure.)
Rabaud C, Burty C, Grandidier M, Christian B, Penalba 
C, Beguinot I, et al. Tolerability of postexposure 
prophylaxis with the combination of zidovudine-
lamivudine and lopinavir-ritonavir for HIV infection. 
Clin Infect Dis 2005;40:303–5. (No comparator.)
Rey D, Partisani M, Hess-Kempf G, Krantz V, Priester 
M, Cheneau C, et al. Tolerance of a short course of 
nevirapine, associated with two nucleoside analogues, in 
postexposure prophylaxis of HIV. J Acquir Immune Defic 
Syndr 2004;37:1454–6. (Chart review.)
Roland ME, Neilands TB, Krone MR, Katz MH, 
Franses K, Grant RM, et al. Seroconversion following 
nonoccupational postexposure prophylaxis against HIV. 
Clin Infect Dis 2005;41:1507–13. (No comparison group.)
Schechter M. HIV vaccine evaluation center in Rio de 
Janeiro, Brazil. Vaccine 2002;20:1909–11. (Note.)
Sonder G, Regez R, Brinkman K, Prins J, Mulder J, 
Coutinho R, et al. Postexpositiebehandeling tegen HIV 
buiten het ziekenhuis in Amsterdam, januari-december 
2000. Ned Tijdshr Geneeskd 2002;146:629–33. (Non-
English.)
Timset F, Maillard A, Spindler E, Taquin Y, Deniaud, 
Ferchal F, et al. Traitment antirétroviral prophylactique 
après exposition sexuelle au VIH: 93 cas. Ann Dermatol 
Venereol 2002;129:866–9. (Non-English.)
Winston A, McAllister J, Amin J, Cooper DA, Carr A. 
The use of a triple nucleoside–nucleotide regimen for 
nonoccupational HIV post-exposure prophylaxis. HIV 
Med 2005;6:191–7. (Case note review.)
Cost-effectiveness studies
Allen UD, Read S, Gafni A. Zidovudine for 
chemoprophylaxis after occupational exposure to HIV-
infected blood: an economic evaluation. Clin Infect Dis 
1992;14:822–30. (Occupational exposure.)
Barham L, Lewis D, Latimer N. One to one interventions 
to reduce sexually transmitted infections and under 
the age of 18 conceptions: a systematic review of the 
Appendix 3  
List of excluded studiesAppendix 3
46
economic evaluations. Sex Transm Infect 2007;83:441–6. 
(Not PEP.)
Creese A, Floyd K, Alban A, Guinness L. Cost-
effectiveness of HIV/AIDS interventions in Africa: a 
systematic review of the evidence [erratum appears in 
Lancet 2002;360:880]. Lancet 2002;359:1635–43. (Not 
PEP.)
Forst LS, Fletcher B. HIV prophylaxis for health 
care workers. J Occup Environ Med 1997;39:1212–19. 
(Occupational exposure.)
Greub G, Gallant S, Zurn P, Vannotti M, Burgisser P, 
Francioli P, et al. Spare non-occupational HIV post-
exposure prophylaxis by active contacting and testing 
of the source person. AIDS 2002;16:1171–6. (Not an 
economic evaluation.)
Hornberger J. A systematic review of cost–utility analyses 
in HIV/AIDS: implications for public policy. Med Decis 
Making 2007;27:789–821. (Not an economic evaluation 
of PEP.)
Marin MG, Van LJ, Yee A, Bonner E, Glied S. Cost-
effectiveness of a post-exposure HIV chemoprophylaxis 
program for blood exposures in health care workers. 
J Occup Environ Med 1999;41:754–60. (Occupational 
exposure.)
Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-
effectiveness of chemoprophylaxis after occupational 
exposure to HIV. Arch Intern Med 1997;157:1972–80. 
(Occupational exposure.)
Scheid DC, Hamm RM, Stevens KW. Cost-effectiveness 
of human immunodeficiency virus postexposure 
prophylaxis for healthcare workers. Pharmacoeconomics 
2000;18:355–68. (Occupational exposure.)© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Appendix 4  
Data extraction of clinical effectiveness study
Reference and 
design Intervention Participants Outcome measures
Author: 
Schechter et al.21
Year: 2004
Country: Brazil
Study design: 
cohort study
Number of 
centres: one
Funding: 
GlaxoSmithKline, 
Conselho 
Nacional de 
Desenvolvimento 
Científico e 
Tecnológico, 
National Institute 
of Allergy and 
Infectious 
Diseases 
(research career 
award), Fogarty 
International 
Center (grant)
Intervention: 
postexposure 
prophylaxis (PEP): 
zidovudine 300 mg 
and lamivudine 
150 mg orally, fixed 
dose combination 
tablet, twice daily 
for 28 days
Initial 4-day supply 
of zidovudine 
and lamivudine 
to be taken post 
eligible exposure; 
additional 24-day 
supply provided for 
exposures deemed 
eligible by study 
personnel
Subjects were 
instructed to 
begin taking the 
study regimen 
immediately 
after eligible 
exposures and in 
no circumstances 
> 48 hours after 
the exposure
Control: no PEP
Number of participants: 200 enrolled in the 
study
Intervention: 68 took PEP at least once; 
control: 132
Sample attrition/dropout: 94% (n = 187) 
followed up for 24 months or until 
seroconversion; two excluded immediately 
because they had no follow-up data; seven 
(53.9%) had last interview at 6 months; two 
(15.4%) had last interview at 12 months; 
four (30.8%) had last interview at 18 months
Inclusion criteria for study entry: male 
gender, confirmed HIV seronegativity, 
reported homosexual or bisexual behaviour, 
sexually active, defined as anticipated sexual 
activity in the next 6 months, willingness to 
use PEP after high-risk exposures, age 18–35 
years
Exclusion criteria for study entry: high-risk 
exposures for HIV in the previous 48 hours, 
anaemia, leukopenia or hepatic enzyme 
abnormalities at baseline, history of allergy or 
intolerance to any of the study medications
Characteristics of participants: the cohort 
was recruited from former participants of an 
HIV seroincidence study conducted among 
high-risk men who have sex with men
Intervention: see baseline characteristics 
table below
Control: 132 did not take PEP – 86 did 
not take PEP despite reporting at least one 
instance of high-risk behaviour, 46 denied any 
high-risk behaviours during the study period
Outcomes: reported behaviour, 
PEP utilisation, adverse events, 
incident HIV infection
Observed and expected incidences 
were compared
Method of assessing outcomes: 
detailed history taken at each 
visit, physical examination with 
focus on the presence of sexually 
transmitted diseases. Laboratory 
evaluation to assess for potential 
medication toxicity at baseline, 12- 
and 24-month visits. Participants to 
report symptoms consistent with 
severe toxicity. For participants 
who seroconverted during the 
study and who previously used 
PEP , polymerase chain reaction 
was performed on blood samples 
at the beginning and end of the 
PEP course to ensure that the 
seroconversion was unrelated 
to that exposure. Additional 
laboratory evaluations were 
undertaken for persons who took 
PEP based on symptoms that could 
have been caused by the study 
medications or if there were other 
medical reasons to suspect an 
increased likelihood of PEP-related 
side effects
HIV seroconversion was 
defined as HIV enzyme-linked 
immunoabsorbent assay (ELISA) 
seronegativity at the baseline visit 
with a subsequent positive ELISA 
and western blot during a follow-
up visit
Study participants were recruited from 
a well-characterised HIV incidence study 
cohort. The authors took the relationships 
between follow-up time, previously identified 
risk factors for new HIV infection and HIV 
incidence and applied them to the current 
cohort to produce an expected number of 
incident HIV cases in the absence of PEP
Participants who did not start PEP were 
instructed to return every 6 months for an 
evaluation
Drug-resistant HIV was assessed 
for the one participant in whom 
PEP failed
Recruitment dates: July 1995–June 
1998
Follow up: median 24.2 months
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Baseline characteristics PEP (n = 68) No PEP (n = 132) Total (n = 200) p-value 
Age (years), median 28 28 28 p = 0.83
Race, n (%):
  White 34 (50) 60 (45) 94 (47) p = 0.69
  Black 15 (22) 26 (20) 41 (21)
  Mixed 3 (4) 11 (8) 14 (7)
  Other 16 (24) 35 (27) 51 (26)
Completed high school, n (%) 55 (81) 93 (70) 148 (74) p = 0.11
Income per month (Brazilian 
reais), median
445 480 465 p = 0.57
Receptive anal sex last 6 
months, n (%)
48 (71) 84 (64) 132 (66) p = 0.33
Unprotected receptive anal 
sex last 6 months, n (%)
23 (34) 34 (26) 57 (29) p = 0.23
Insertive anal sex last 6 
months, n (%)
46 (68) 93 (70) 139 (70) p = 0.68
Unprotected insertive anal 
sex last 6 months, n (%)
20 (29) 39 (30) 59 (30) p = 0.98
History of gonorrhoea last 6 
months, n (%)
7 (10) 32 (24) 39 (20) p = 0.02
Illicit drug use, n (%) 8 (12) 17 (13) 25 (13) p = 0.82
Hepatitis B core antibody 
positive, n (%)
23 (34) 34 (26) 57 (29) p = 0.22
Comments: The two groups were comparable on age, race, education, income, risk behaviours at enrolment, illicit drug use 
and hepatitis B seroprevalence 
Outcomes: HIV incidence PEP (n = 68) No PEP (n = 132) p-value
Seroconversion to HIV 1 10 Not reported
Comments: 11 subjects had new HIV infections during the course of the study, for an overall seroincidence of 2.9 per 100 
person-years (95% CI 1.4–5.1). Based on the risk profile of the study participants and the experience of the authors’ previous 
cohort study the expected number of new HIV infections was 11.8 (p > 0.97 compared with the observed 11 infections), for 
an expected seroincidence of 3.1 per 100 person-years (p > 0.97 compared with the observed seroincidence of 2.9)
Outcomes: PEP use (28-day 
course)
PEP (n = 68) No PEP (n = 132) p-value
Prescribed once, n (%) 49 (72.1) – –
Prescribed twice, n (%) 14 (20.6) – –
Prescribed three times, n (%) 2 (2.9) – –
Prescribed four times, n (%) 2 (2.9) – –
Prescribed nine times, n (%) 1 (1.5) – –
PEP utilisation: PEP was initiated a total of 109 times by 68 participants. A total of 100 were considered eligible exposures, 
for which a 4-week course was prescribed (see above). The most common reasons for not initiating PEP (≥ one possible 
response per participant) were sex with a steady partner (n = 150), participant did not consider the exposure to be of 
sufficiently high risk to warrant PEP (n = 94) and concerns about side effects (n = 23)© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Outcomes: non-completed PEP courses PEP (n = 68) No PEP (n = 132) p-value
Did not return to complete course, n 2 – –
Discontinued because of adverse events, n 7 – –
Adverse events: At least one side effect was reported in 82% of episodes of PEP use; nausea was the most commonly 
reported side effect and six discontinuations (of those for adverse events) were due to this. One patient with a history of 
pancreatitis was instructed to stop taking PEP because of an asymptomatic increase in pancreatic enzymes. Apart from this 
there were no clinically significant laboratory abnormalities among participants who took PEP .  
Adherence: The full 28-day regimen of PEP was completed for 89 (89%) of the eligible exposures, including the participant 
who seroconverted. 
Outcomes: risk behaviours PEP (n = 68) No PEP (n = 132) p-value
Median number of male partners 6 months 
before baseline (range)
4 (0–50) 2 (0–40) PEP: p = 0.43; 
no PEP: 
p = 0.46
Median number of male partners 6 months 
before last visit (range)
4 (0–180) 2 (0–100) PEP: p = 0.43; 
no PEP: 
p = 0.46
Authors state that, on average, reported high-risk sexual activities declined over time for both PEP and non-PEP users
Risk behaviours PEP (n = 68) No PEP (n = 132)
6 months before 
baseline
6 months 
before last visit
p-value 6 months 
before 
baseline
6 
months 
before 
last visit
p-value
Unprotected anal 
intercourse, n (%)
32 (47.1) 27 (39.7) p = 0.35 48 (36.4) 32 
(24.2)
p = 0.008
Unprotected oral 
intercourse, n (%)
16 (23.5) 8 (11.8) p = 0.06 32 (24.4) 16 
(12.2)
p = 0.002
Unprotected vaginal 
intercourse (%)
1.6 4.7 p = 0.16 6.1 8.3 p = 0.26
Additional comments
The study regimen was chosen because, at the time of the study, a two-drug regimen was recommended for most HIV  •	
exposures that warrant PEP
PEP failure was defined as a documented HIV seroconversion that occurred within 2 months after the exposure for  •	
which PEP was taken. Seroconversions that occurred ≥ 2 months after the exposure for which PEP was taken were not 
considered as PEP failures
Methodological comments
Allocation to treatment groups: Participants decided whether to initiate PEP after a high-risk exposure. For seroconversion  •	
to HIV PEP users were compared with non-users
Blinding: No blinding of assessors at follow-up visits •	
Comparability of treatment groups: The groups that were compared within this study for seroconversions, PEP vs no PEP ,  •	
were comparable at baseline 
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Method of data analysis: Data analysis was performed using SAS version 6.12. Comparisons between groups were analysed  •	
using chi-squared tests for categorical variables and Wilcoxon rank sum tests for continuous variables. Comparisons of 
numbers of male partners at 6 months before baseline and at last interview were analysed using the signed rank test. 
Behaviour practices over time were examined using the McNemar test. Authors used the final interview that individuals 
participated in for those participants who did not have a 24-month interview. Incidence rates are expressed as the 
incidence of seroconversions per 100 person-years of follow-up and exact 95% confidence limits were calculated.
The ‘control’ was modelled by fitting a binomial regression model to the first cohort data with a complementary log (–log)  •	
link function that accounts for previously identified risk factors for incidence of HIV in that cohort. The coefficients from 
that model were applied to the covariate and follow-up patterns of current participants to calculate the expected number 
of HIV seroconversions and expected HIV seroincidence
Sample size/power calculation: No power calculation was performed •	
Attrition/dropout: A cohort of 200 was enrolled; of these 68 took the study drug 109 times •	
General comments
Generalisability: The cohort was recruited from former participants of an HIV seroincidence study conducted among high- •	
risk men who have sex with men aged 18–35 years
Outcome measures: The outcome measures were relevant to the study area •	
Intercentre variability: N/A •	
Conflicts of interest: Study was funded by GlaxoSmithKline, Conselho Nacional de Desenvolvimento Científico e  •	
Tecnológico, National Institute of Allergy and Infectious Diseases (research career award), Fogarty International Center 
(grant)© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Data extraction of cost-effectiveness studies
Study characteristics
Study Pinkerton et al. 199822
Country of origin US
Base year prices 1996 US$
Intervention Postexposure prophylaxis (PEP) following potential HIV exposure through sexual contact 
with a partner who may or may not be infected, compared with a ‘no programme 
option’. PEP was assumed to consist of a 4-week regimen of triple combination therapy 
with zidovudine (ZDV), lamivudine (3TC) and the protease inhibitor indivadir and was 
assumed to be as effective as ZDV monotherapy in the occupational setting 
Study type Cost–utility analysis; decision-analytical model to evaluate cost-effectiveness
Study group A hypothetical cohort of 10,000 patients who reported sexual intercourse with a partner 
of unknown HIV status
Perspective Societal 
Industry role None stated
Effectiveness parameter Probability PEP effective 0.79 from occupational study26 
Costs assessment  Primary cost of PEP is drug therapy: cost of PEP triple therapy per patient: US$619. 
Obtained from published literature (references given)
Utilities assessment Quality-adjusted life-years (QALYs) saved per infection prevented: 11.23. Obtained from 
published literature (references given)
Ranges for sensitivity analyses  Effectiveness: 0.43–0.94
Costs: US$400–955
QALYs saved: 13.18–9.34
Study base case ‘headline’ 
predictions/findings
PEP should be restricted to partners of infected persons, to patients reporting 
unprotected receptive anal intercourse and possibly to cases where there is substantial 
likelihood that the partner is infected
Results
Base case Authors use predetermined threshold of US$50,000 per QALY saved
The base-case analysis for a cohort of 10,000 patients receiving PEP reported: 19.62 
HIV infections averted following receptive anal intercourse; 0.59 HIV infections averted 
following insertive anal intercourse; 0.11 HIV infections averted following receptive 
vaginal intercourse; and 0.07 HIV infections averted following insertive vaginal intercourse
Authors report that prophylaxis is not cost-effective for sex act/role combinations other 
than receptive anal intercourse (all cost–utility ratios exceed US$750,000 per QALY 
saved)
They also report that PEP following receptive vaginal intercourse appears to be cost-
effective if certain that the partner is infected [HIV prevalence (probability of HIV 
infection) has to be > 0.73]
PEP following insertive exposures is reported to be marginally cost-effective at best (the 
cost–utility ratio is > US$100,000 per QALY saved regardless of the probability of HIV 
infection)
The cost–utility ratio for ZDV/3TC PEP following receptive anal intercourse among men 
who have sex with men is US$6354 per QALY saved
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Sensitivity analysis The sensitivity analyses indicated that the results for the receptive anal case were not 
sensitive to changes in the parameter values and PEP was always cost-effective across a 
range of values
Both the insertive anal and insertive vaginal cases were not sensitive and were not cost-
effective across a (plausible) range of values. The receptive vaginal case was sensitive to 
the probability of the sexual partner of the patient being HIV infected. In this case, if the 
probability of infection is > 0.73 then PEP may be cost-effective
PEP is cost saving for receptive anal intercourse if the probability that the partner is 
infected is > 0.25
Triple PEP therapy was unlikely to be cost-effective relative to dual combination PEP (the 
additional drug costs will not be offset by treatment savings)
The results did not appear to be sensitive to repeated exposure and PEP
Conclusions
PEP following suspected sexual exposure to HIV is only cost-effective for receptive anal 
intercourse or receptive vaginal intercourse with a partner who is likely to be infected
If the probability that the partner is infected is very small then PEP may not be cost-
effective following receptive anal intercourse
PEP after insertive vaginal intercourse or insertive anal intercourse is probably not cost-
effective, regardless of the partner’s risk status
The authors report that from a purely economic standpoint PEP should be restricted 
to partners of infected persons (e.g. serodiscordant couples), to patients reporting 
unprotected receptive anal intercourse (including condom breakage) and possibly to 
cases in which there is a substantial likelihood that the partner is infected. Providing PEP 
to all who request it does not appear to be an economically efficient use of limited HIV 
prevention and treatment resources
Caveats
Uncertainty in the effectiveness of PEP has implications for its cost-effectiveness
Authors have assumed that PEP is completely ineffective when the antiretroviral regimen 
is discontinued prematurely
Analysis assumes that all individuals receiving PEP are uninfected and that PEP therefore 
can prevent an infection. Therefore, the above results may disproportionately overstate 
the cost-effectiveness of PEP in high prevalence communities
PEP for receptive anal intercourse may not be cost-effective (authors state US$100,000 
per QALY) if the probability that the partner is infected is quite small
There are limitations with the per-contact probabilities: they are not known with 
certainty and the probable ranges may overlap. Stage of disease, viral load, genetics 
and facilitation by sexually transmitted diseases are believed to also affect the risk of 
transmission; even greater uncertainty surrounds the probability of transmission for oral 
sex © 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Study Pinkerton et al. 200423
Country of origin US
Base year prices 2000 US$
Intervention An initial 7-day supply of antiretroviral medication; additional 21 days supplied at follow-up visit 
7 days later
The protocol for this study included discussion of potential benefits and negative consequences 
of PEP , medical evaluation, HIV risk assessment, risk reduction counselling and medication 
adherence counselling, and information on previous antiretroviral use and response to 
medication of HIV-infected sources was obtained if possible to tailor the regimen offered as PEP 
to one to which the infection would most likely be susceptible. Base-case values were assigned 
to these parameters
Study type Cost–utility study
Study group 401 participants with possible non-occupational exposure to HIV [sexual, needle sharing, non-
occupational needlestick injury, other (bite or assault)]. Distribution of patients was by exposure 
type, percentage of patients who completed PEP in each exposure group and proportion of 
completers with a known HIV-infected source. Patients who reported multiple exposures were 
classified according to the highest risk exposure. In total, 312 patients (78%) were known to 
have completed the PEP regimen; 46% reported that they knew that their source was infected 
with HIV
Perspective Societal: included all identifiable costs, regardless of who bore these
Industry role None stated (one of the authors has received honorariums from GlaxoSmithKline, Bristol-Myers 
Squibb and Agouron Pharmaceuticals)
Effectiveness parameter Probability PEP effective 0.81 from occupational study27 
Costs assessment Five drug costs (for the five different drugs): US$312, US$267, US$222, US$280 and US$679 
from published literature (reference given)
Itemised laboratory and clinic costs from published literature (reference given)
Wages and travel costs from financial records kept by study investigators
Utilities assessment Quality-adjusted life-years (QALYs) lost per HIV infection: 9.31. Obtained from published 
literature (reference given)
Ranges for sensitivity 
analyses 
Effectiveness: 0.48–1.0
Costs: least expensive regimen US$502 and most expensive regimen US$1258
QALYS saved: 4.28–18.23
Study base case ‘headline’ 
predictions/findings
For this study population, HIV PEP was cost-effective by conventional standards and cost saving 
for persons seeking PEP after male–male receptive intercourse
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Results
Base case Use of PEP reduced the expected number of infections to 0.77 and therefore prevented an 
estimated 1.59 infections (expected infections in the absence of PEP in the exposures reported 
by the 401 patients would be 2.36). The authors have adjusted for continuing risk behaviours 
over the subsequent 10 years and report that PEP in this case would have averted 1.26 infections 
and saved US$281,323 medical care costs and 11.74 associated QALYs
PEP effectiveness was set at 81%
The overall cost–utility ratio was US$14,449 per QALY saved
The authors used thresholds of US$40,000–$60,000 per QALY for cost-effectiveness and 
US$200,000 for non-cost-effectiveness
In total, 96% of averted infections were among men who reported exposure through receptive 
anal intercourse (RAI) with other men. When restricted to this subgroup the PEP programme 
was cost saving
Exposure through injection drugs: US$86,462 per QALY saved; male–female RAI: US$165,289 
per QALY saved
Overall cost–utility ratio for men reporting exposure through male–male sex (receptive or 
insertive anal sex, receptive oral sex or ‘other’) was US$8607 per QALY saved. Cost–utility ratio 
for all other exposures combined was US$258,667 per QALY saved
The PEP programme was cost saving for patients who reported that their partner was HIV 
positive. The cost–utility ratio was US$58,025 when the HIV status of the partner was unknown. 
The authors state that these results are mainly driven by the men with exposures through RAI 
as these were cost-saving; the cost–utility ratio for the 93 patients who were exposed through 
other routes was US$278,671
Authors assumed that patients remained at risk of infection for 10 years after participating in 
the PEP programme, with an annual risk equal to the incidence of infection in the associated 
exposure group
Sensitivity analysis The programme remained cost-effective when the PEP effectiveness parameter was set to 48%
The programme would not be cost saving even if the antiretroviral regimen was 100% effective
The programme was cost-effective for PEP completion rates > 29%
The programme remained cost-effective regardless of the percentage of partners known to be 
infected with HIV or the prevalence of infection among partners whose HIV status was unknown
The results were not sensitive to the HIV-related treatment cost and QALYs saved parameters
The programme was cost-effective provided that at least 2.24 QALYs were saved per averted 
infection and was cost-effective regardless of the cost of treating HIV and AIDS© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Sensitivity analysis The programme was still cost-effective if a 5% discount rate was used. When a 0% discount 
rate was used the cost–utility ratio decreased to US$2385 per QALY saved
The cost–utility ratio was most sensitive to RAI transmission probability. The threshold analysis 
indicated that the PEP programme would be cost saving overall if this probability exceeded 0.033 
and would be cost-effective (cost–utility ratio of US$60,000 per QALY saved) for probabilities as 
small as 0.009 (base case was 0.02)
The programme would not be cost-effective (cost–utility ratio > US$200,000 per QALY saved) 
if the per-exposure transmission probability for RAI was less than 0.003
Using alternative published HIV incidence and prevalence rates for San Francisco: US$11,081 per 
QALY saved, lower than the base-case value
Cost–utility ratio increased to US$71,381 when the transmission probabilities were set to their 
smallest values and decreased to less than zero (cost saving) when they were set to their largest 
values
Conclusions
HIV PEP was cost-effective by conventional standards (here defined as between US$40,000 
and US$60,000) and cost saving for men seeking PEP after male–male RAI. It is possibly cost-
effective for injection drug exposures and women reporting RAI but probably not cost-effective 
for other exposures. Although fewer than half of the patients reported male–male RAI, the PEP 
programme was cost-effective overall and authors suggest an economically sound use of societal 
health promotion resources
Caveats
The effectiveness of PEP after sexual exposures is unknown: authors assumed that dual and 
triple drug PEP was as effective as zidovudine PEP in a case–control study of occupational 
exposures
Differences in the transmission dynamics of sexual (mucosal) and occupational (percutaneous) 
exposures may also impact on PEP effectivenessAppendix 5
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Study Pinkerton et al. 200424
Country of origin US
Base year prices 2000 US$
Intervention Hypothetical PEP programme in 96 US metropolitan statistical areas (MSAs), based on San 
Francisco PEP programme (no further detail provided in this paper)
Study type Cost-effectiveness analysis
Study group Information on PEP clients was taken from the San Francisco PEP programme. Potential 
PEP clients were divided into four risk groups based on exposure type: men who have sex 
with men (MSM), intravenous drug users (IDUs), male/female heterosexuals and other non-
occupational exposures (bites, assaults involving mucosal exposure). It was assumed that 
the same proportion of each group would access PEP in each MSA as they had in the San 
Francisco PEP study. This was then used to estimate the number of potential PEP clients in 
each group in each MSA. Previously published estimates of HIV prevalence in the 96 MSAs for 
each risk group were used. It was assumed that the distribution of PEP-prompting exposures 
(e.g. receptive anal intercourse, injection-related exposure, etc.) in each MSAs would mimic 
the distribution observed in San Francisco. It was also assumed that risk group exposure could 
be inferred from exposure type (e.g. man reporting vaginal intercourse is in heterosexual 
group and source partner belongs to same group; one exception: non-occupational 
needlestick injuries usually come from discarded needles and so the HIV prevalence in IDUs 
was used to estimate the prevalence of infection among needlestick exposure sources)
Perspective Societal
Industry role Not stated
Effectiveness parameter Probability PEP effective 0.81 from occupational study27 
Costs assessment Total cost of PEP programme in a particular MSA was calculated using a formula (given) 
including: drug costs for completers US$597 (non-completers US$454); laboratory work 
completers US$26 (non-completers US$14); other clinical services completers US$523 (non-
completers US$240). Obtained from published literature (references given) and data from San 
Francisco PEP programme data 
Utilities assessment Quality-adjusted life-years (QALYs) saved per infection prevented: 9.31. Obtained from 
published literature (references given)
Ranges for sensitivity analyses  Effectiveness: 0.48–0.94
Costs: not used
QALYs lost: 10.29–8.37
Study base case ‘headline’ 
predictions/findings
Proportion of clients completing therapy was set at 77.8% (based on San Francisco PEP 
study). The effectiveness of PEP in preventing HIV infection was assumed to be 81%, 
based on the findings of a case–control study in health-care workers (HCWs) exposed 
occupationally. Across the 96 MSAs the hypothetical PEP programmes would serve 19,154 
clients at a total cost of US$21.7m, averting 63.9 HIV infections (primarily MSM – 96.1% of 
the averted infections, constituting 75.9% of PEP clients)
Results
Base case The combined cost–utility ratio (CUR) for the 96 MSA was US$12,567 per QALY saved. 
This ranged from US$4137 (San Francisco) to US$39,101 (Stockton-Lodi MSA) per QALY 
saved. Only two MSAs had CUR greater than US$30,000. The mean and median CUR were 
US$15,728 and US$15,367 respectively
PEP was cost saving (CUR < US$0) for male–male and male–female receptive anal 
intercourse exposures
The CUR for needle-sharing exposures and needlestick exposures was US$97,867 and 
US$159,686 respectively
CUR exceeded $380,000 per QALY saved for all other types of exposure© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Sensitivity analysis Key parameters were varied one at a time in univariate sensitivity analyses. Only one of the 
parameter manipulations (reducing the per-exposure transmission probability for receptive 
anal intercourse from 0.02 to 0.008) resulted in a CUR > US$60,000 per QALY saved.
Individually varying the other transmission probabilities within plausible ranges produced 
< 4% deviation from the base CUR
Several prevalence-related measures were moderately to strongly correlated with the inverse 
of the CUR values for individual MSAs (although overall the CUR across the 96 MSAs was not 
especially sensitive to the prevalence of infection)
The authors report that the results were moderately sensitive to the effectiveness of PEP 
and somewhat sensitive to the proportions of persons who completed the PEP regimen, 
the proportion of PEP clients with known infected source partners and the lifetime costs of 
medical care and lost QALYs associated with a case of HIV infection
In particular, the proportion of the ‘high-risk’ MSM, IDUs, heterosexual subpopulation 
classified as HIV-infected MSM was strongly correlated with the inverse CUR
Conclusions
PEP for HIV could be a cost-effective adjunct to existing HIV prevention efforts
Overall across the 96 MSAs, PEP was cost saving for receptive anal intercourse and possibly 
cost-effective for needle sharing and non-occupational needlestick injuries, but of questionable 
economic value for all other types of exposure
PEP was highly cost-effective for MSM, less so for IDUs and high-risk women, and probably 
not cost-effective for general population exposures or heterosexual men
Caveats
The effectiveness of PEP in preventing infection and the per-exposure transmission probability 
are not established. HIV prevalence and population size estimates were based on a study 
published in 1996 (therefore reflecting HIV epidemiology in the early 1990s). Analysis did 
not take into account the ages of clients (which would affect the number of QALYs lost to 
infection) or whether or not a particular client completed the PEP regimen or was known 
to have been exposed to HIV by an HIV-positive partner. The analysis assumed that the 
distribution of client exposure groups in each MSA would mimic that observed in the San 
Francisco study. Implementation of PEP services in a given locale is likely to differ from the 
San Francisco experienceAppendix 5
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Study Herida et al. 200625
Country of origin France
Base year prices 2002 Euros
Intervention Comparison of PEP programme with ‘no PEP’ alternative. For patients in PEP programme 
clinicians prescribe drugs of their choice (usually tri-therapy containing protease inhibitor). HIV/
hepatitis B/hepatitis C serology tests, a pregnancy test and ‘other’ laboratory tests carried out 
at the baseline visit. Three follow-up visits scheduled at days 15, 30 and 90 after exposure. 
Laboratory tests scheduled at day 15. HIV and hepatitis serology is repeated at day 30 (end of 
treatment), 120 and 180. PEP physician provides patient with 4-week supply of antiretroviral 
drugs and counselling at each visit. Information on patients’ characteristics, risk of exposure, 
treatments prescribed, serology and potential adverse effects were recorded by clinicians during 
follow-up visits and entered in an anonymous database. A total of 15 drugs were used in various 
two-drug (9%), three-drug (90%) and four-drug (1%) combinations
Study type Cost-effectiveness analysis based on decision tree. As parameters vary according to exposure 
risks, a separate decision tree was built for each type of exposure event
Study group 12,551 individuals sought PEP between July 1999 and December 2003. Of these, 8958 (71%) 
were prescribed PEP and included in a national hospital-based voluntary surveillance of PEP 
programme for both occupational and non-occupational exposure (set up in 1999); 6812 (76%) 
of those prescribed PEP had a sexual exposure event, 2092 (23.4%) had an occupational 
exposure event (68.9% of these were HCWs) and 54 (0.6%) were exposed through sharing 
drug injection equipment. In the sexual exposure group, 2546 (28.4%) were men who have 
sex with men (MSM) and 4266 (47.6%) were heterosexual. The source was known to be HIV 
infected for 2413 individuals (27.1%)
Perspective Societal
Industry role Not stated
Effectiveness parameter Probability PEP effective 0.80 from occupational study27 (in fact, 0.81 from reference)
Costs assessment Total cost: €988; cost of PEP therapy per patient: €745; physician visits: €80; laboratory costs: 
€163. Obtained from PEP treatment prescribed between 1999 and 2003 using published prices 
(reference given)
Utilities assessment Quality-adjusted life-years (QALYs) saved per infection prevented: 8.34. Obtained from 
published literature (references given)
Ranges for sensitivity 
analyses 
Effectiveness: 0.48–0.94
Costs: not used
QALYs saved: 11.58–4.31
Study base case ‘headline’ 
predictions/findings
Number of infections averted and number of QALYs saved during 1999–2003. On the basis of 
the model it was estimated that among 8958 treated individuals, 12 cases of HIV infection would 
have occurred if none had received PEP and 4.3 cases would have occurred if all had received 
PEP
Results
Base case Five individuals became infected during follow-up – two were considered PEP failures (receptive 
anal intercourse in a gay man and a women); the three remaining patients (all MSM) were 
considered by physicians to have seroconversions resulting from high-risk sexual behaviour after 
the PEP treatment
Cost of the PEP programme (providing PEP to 8958 individuals) was estimated at €7,670,002 
and the cost-effectiveness ratio (CER) at €996,104 per infection averted
The total cost of the programme (including the cost of caring for the estimated 4.3 cases of HIV 
infection that occurred among the 8958 treated individuals) was €3,035,075
The cost of caring for the estimated 12 cases of HIV infection that would have occurred without 
the PEP programme was €8,752,150
The estimated marginal cost was €5,717,075 and the CER was €88,692 per QALY saved© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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There were major differences in the CER according to the type of exposure. PEP after receptive 
anal intercourse with an HIV-infected individual was cost saving in men and women (negative 
ratio of €22,141 and €22,031 per QALY saved respectively). PEP after an intravenous drug user 
(IDU) sharing needle with an HIV-infected person was cost saving (€1141 per QALY saved). 
PEP is cost-effective (< €50,000 per QALY saved) for HCW after percutaneous exposure to 
material from an HIV-infected patient, and for MSM having receptive anal intercourse with a 
partner of unknown status. These five exposures accounted for 15.7% of prescriptions. In other 
exposures PEP was not considered cost-effective: 72% of exposures had CER > €200,000 per 
QALY saved and 52% of cases had CER > €2m per QALY saved
Sensitivity analysis One-way sensitivity analyses were performed on compliance according to the low estimation 
of the compliance, and on life expectancy of HIV-infected individuals according to the higher 
lifetime HIV cost resulting from longer survival (other parameters were kept fixed at base-case 
values)
Patients with missing follow-up information were considered as compliant as those known to 
have attended the 1-month follow-up (this compliance was used in the base case); patients with 
missing follow-up information were considered as lost to follow-up with a compliance = 0 (this 
estimated compliance was used in the sensitivity analysis). In this case the programme would 
prevent 3.8 infections and save 31.7 QALYs at a marginal cost of €5,087,998, resulting in a CER 
of €160,382 per QALY saved. As before, PEP after receptive anal intercourse with an HIV-
infected individual remains cost saving (–€17,778 and –€18,860 per QALY saved for MSM and 
heterosexual women respectively). PEP to an IDU after needle sharing with an HIV-infected 
person remains cost-effective but is no longer cost saving (€18,445 per QALY saved)
One-way sensitivity analyses were performed on the life expectancy of HIV-infected individuals 
according to the higher value of life expectancy and higher lifetime HIV cost resulting from 
longer survival (16.82 QALYs compared to base case of 12.79, and €331,869 lifetime HIV/AIDS 
care costs compared to base case of €252,768; both costs and QALYs are discounted at 3%). 
According to this scenario the programme is less cost-effective than the base case (33.3 QALYs 
prevented at marginal cost of €5,105,998; CER = €153,241 per QALY saved). The three 
exposure risks with negative ratios in the base-case analysis remain cost saving but with higher 
cost ratios
Threshold analyses were performed for exposures with CER under €200,000 per QALY saved, 
using minimum values of prevalence, per-contact HIV transmission or compliance required to 
achieve the cost-saving threshold (€0 per QALY saved) or the cost-effective threshold (€50,000 
per QALY saved). PEP for MSM after receptive anal intercourse with a partner of unknown HIV 
status would be cost saving for a per-contact transmission risk of at least equal to 0.0411 or an 
HIV prevalence of at least 0.208. After needle sharing with an individual of unknown serostatus, 
to achieve cost-effectiveness (€50,000 per QALY saved) the compliance should be ≥ 0.92 with 
both the highest values of prevalence (0.21) and of the per-contact transmission risk (0.0092). 
For receptive vaginal intercourse with an HIV-infected partner, a per-contact transmission risk 
equal to 0.0208 would allow the CER to be reached
Conclusions
According to international standards that use US$50,000 per QALY saved as a threshold, the 
French PEP programme appears not to be a cost-effective intervention; only 15.7% of PEP 
courses in the French programme can be considered cost-effective
The PEP programme is less cost-effective than other French prevention or screening 
programmes
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Caveats
The authors list several limitations. They had to make several initial assumptions (and used 
sensitivity analyses to overcome this). Compliance could only be estimated for 47% of 
PEP prescriptions and so overall compliance was estimated at 0.75. Any overestimation of 
compliance would improve the CER (demonstrated in the sensitivity analysis by using low 
estimate of compliance)
There are no available data for lifetime HIV/AIDS costs in France and so the authors estimated 
these
The model did not take into account the possibility that some patients seeking PEP may continue 
at-risk behaviour
The study did not consider PEP adverse events. The authors state that taking these into account 
would further reduce the CER of the overall PEP programme: 65% of 2138 treated patients 
in the French PEP programme had clinical adverse events and 8% presented with biological 
abnormalities
The number of HIV infections predicted by the model was higher than that seen; however, HIV 
serology 6 months after PEP initiation was only available for 18% of patients and so the true 
number of PEP failures may be higher© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
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Feedback
The HTA Programme and the authors would like to know  
your views about this report.
The Correspondence Page on the HTA website  
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.